Loading
  • Facebook
  • LinkedIn
  • Twitter
  • Instagram
  • Pinterest
  • Youtube
  • Mail
  • Rss
  • Log In
    • Register
Contacts us @ MediPr.org
Medical Writer Agency | 醫學作家香港 | 醫學寫作 | MediPR | MediPaper Hong Kong
  • MDnews
  • About [‘mediPr]
  • Search
  • Menu Menu
Warning

THIS POST CONTAINS ‘OFF-LABEL’ INFORMATION ON INDICATIONS NOT YET APPROVED BY THE US FDA

Non-sponsored Content

Share this entry
  • Share on Facebook
  • Share on Twitter
  • Share on WhatsApp
  • Share on Pinterest
  • Share on LinkedIn
  • Share by Mail


Brief Communication

Making Sense of Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)

Medical writer: Stijn van den Borne, MSc | Last updated: 26th March 2018 | In: Guidelines, ImmunoOncology, Immunotherapy, Lung Cancer, Oncology

Rapid development and fast-tracked approvals of immune-checkpoint inhibitors have led to the first registration in non-small cell lung cancer (NSCLC) in 2015. Just over two years later, immunotherapies start to dominate the frontline treatment of NSCLC. This expansion of therapeutic options will soon reflect in dramatic changes to the treatment guidelines, where immunotherapies are expected to complement the chemotherapeutic options. A brief communication of the relevant immuno-oncology data in NSCLC.

Article Keywords

AstraZeneca, atezolizumab, Avastin, AZ, bevacizumab, BMS, Bristol-Myers Squibb, carboplatin, cisplatin, CTLA4, docetaxel, durvalumab, gemcitabine, Genentech, Imfinzi, ipilimumab, Keytruda, Merck, MSD, nivolumab, Opdivo, paclitaxel, PD-1, PD-L1, pembrolizumab, pemetrexed, Roche, Tecentriq, Yervoy

Making sense of immunotherapy in NSCLC pembrolizumab NSCLC nivolumab NSCLC ipilimumab NSCLC atezolizumab NSCLC durvalumab NSCLC Keytruda NSCLC Opdivo NSCLC Yervoy NSCLC Tecentriq NSCLC Imfinzi NSCLC

Register or login to download the PPT

Pembrolizumab immunotherapy in the 1st-line NSCLC

In the open-label Phase II KEYNOTE-021 study, the addition of pembrolizumab to carboplatin and pemetrexed in patients with non-squamous NSCLC (N=123) improved the overall response rate (ORR) to 55% from 29% with the doublet alone (P=0.0032). An improvement regardless of PD-L1 expression. The median progression-free survival (PFS) was 13.0 months with the addition of pembrolizumab vs 8.9 months for the pemetrexed/carboplatin doublet (HR=0.53, P=0.0205, 95% CI, 0.31-0.91). Patients in the pembrolizumab arm continued to receive the immunotherapy up to 24 months. After a median 10.6 months follow-up, 88% of patients in the experimental-arm remained alive and progression-free compared to 78% of patients receiving the doublet.

The multi-centre, double-blind, Phase III KEYNOTE-189 trial confirmed the early results of the KEYNOTE-021 study. In the KEYNOTE-189 study, 616 EGFR- or ALK-negative non-squamous NSCLC patients were randomised 2:1 to receive frontline pembrolizumab or placebo in combination with pemetrexed and a platinum salt. The co-primary endpoints of improved overall survival (OS) and PFS were met and published in the New England Journal of Medicine in April 2018.

Single-agent pembrolizumab

At a median follow-up of 25.2 months in the open-label KEYNOTE-024 study, pembrolizumab more than doubled median OS compared to platinum-based chemotherapy in 154 NSCLC patients with a PD-L1 expression ≥50% and negative EGFR- or ALK-status. Single-agent pembrolizumab led to a 30.2 months OS vs 14.2 months with chemotherapy (HR=0.63, P=0.002; 95% CI, 0.47-0.86) despite the crossover of 82 patients from the chemotherapy-arm to the pembrolizumab-arm. The 24-month OS-rate favoured pembrolizumab vs platinum doublet: 51.5% vs 34.5% respectively and the ORR was 45.5% in the pembrolizumab-arm compared to 29.8% in the chemotherapy-arm.

Common pembrolizumab-related side effects.

Durvalumab for maintenance after frontline chemoradiotherapy in NSCLC

The phase III PACIFIC trial (N=709) randomised patients 2:1 to either receive durvalumab or placebo after chemoradiotherapy. Durvalumab-maintenance therapy was associated with improved median PFS, 16.8 months in the durvalumab-group vs 5.6 months in the placebo group (HR=0.52, P<0.0001; 95% CI, 0.42-0.65). The 12-month and 18-month PFS-rates both favoured the immunotherapy: 55.9% (durvalumab) vs 35.3% (placebo) and 44.2% (durvalumab) vs 27.0% (placebo) respectively, and was irrespective of PD-L1 expression before chemoradiotherapy. Durvalumab treatment was associated with a higher ORR of 28.4% vs 16.0% with placebo. Patients with a response to the immune-checkpoint inhibitor had durable, ongoing responses of 72.8% at both 12 and 18 months. In the placebo-arm, the 12- and 18-month ORRs were 56.1% and 46.8%, respectively.

Common durvalumab-related side effects.


Newsletter Sign-Up

Do you like our content? Subscribe to our non-intrusive newsletter today! We promise we won’t be spammy.

YOU MAY ALSO LIKE

the-evolving-role-of-nk1-in-cinv-management-chemotherapy-induced-nausea-vomiting-akynzeo-nepa-palonosetron-netupitant

The evolving role of NK1 in CINV management

https://medi-paper.com/wp-content/uploads/2021/04/the-evolving-role-of-nk1-in-cinv-management-chemotherapy-induced-nausea-vomiting-akynzeo-nepa-palonosetron-netupitant-e1618546071115.jpg 1024 1917 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2021-04-16 09:17:092021-04-20 13:49:08The evolving role of NK1 in CINV management
Lung Cancer Update April 2021

Lung Cancer Update April 2021

https://medi-paper.com/wp-content/uploads/2021/04/Lung-Cancer-Update-April-2021.jpg 1000 1500 Kirsty LEE https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Kirsty LEE2021-04-08 16:28:082021-04-16 10:06:17Lung Cancer Update April 2021
Abemaciclib A review of the evidence through clinical case

Abemaciclib: A review of the evidence through clinical cases

https://medi-paper.com/wp-content/uploads/2021/03/Abemaciclib-A-review-of-the-evidence-through-clinical-case.jpg 1000 1500 Kirsty LEE https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Kirsty LEE2021-03-25 15:09:132021-04-20 13:51:14Abemaciclib: A review of the evidence through clinical cases
The Role of Patient Blood Management for Inflammatory Bowel Disease-01

The Role of Patient Blood Management for Inflammatory Bowel Disease

https://medi-paper.com/wp-content/uploads/2021/02/The-Role-of-Patient-Blood-Management-for-Inflammatory-Bowel-Disease-01.png 1024 1917 Kirsty LEE https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Kirsty LEE2021-02-27 19:09:322021-03-02 17:48:41The Role of Patient Blood Management for Inflammatory Bowel Disease
PreviousNext
Breast-Cancer-Update-2021
1st February 2021

Breast cancer update January 2021

ASCO 2019 lung cancer NSCLC ASCO19 SCLC mesothelioma KEYNOTE-189 KEYNOTE-001 IMpower150 MYSTIC LCMC3 Lung-MAP S1400G S1400I Flaura CALGB 30901 DETERRED COMPASS
12th June 2019

ASCO 2019 Lung Cancer: 36 Oral Presentations of the ASCO19 lung cancer track summarised

Nivolumab plus ipilimumab immunotherapy in front-line NSCLC

Preliminary results of the Phase III CheckMate 227 show that the combination of nivolumab and ipilimumab improves PFS when compared with chemotherapy in treatment-naïve patients with high mutation burden (high-TMB) NSCLC. The co-primary PFS endpoints was met and published in the New England Journal of Medicine in April 2018.

Common nivolumab and ipilimumab-related side effects.

Atezolizumab immunotherapy in the 1st-line treatment of NSCLC

In the multicenter, open-label Phase II IMpower131, the addition of atezolizumab to 4 or 6 cycles of carboplatin and nab-paclitaxel in the 1st-line delayed progression or death compared with chemotherapy alone in patients with advanced squamous non–small cell lung cancer (NSCLC). The co-primary endpoints were PFS and overall survival OS and the latter was not improved. The results have not yet been published.

The Phase III IMpower150 trial previously showed that the addition of atezolizumab to bevacizumab, carboplatin, and paclitaxel delayed progression or death by 38% in patients with advanced non-squamous NSCLC. The median PFS improved to 8.3 months compared with 6.8 months for bevacizumab and chemotherapy alone (HR=0.62, P<0.0001; 95% CI=0.52-0.74). The 12-month PFS-rate was 37% after addition of atezolizumab vs 18% for bevacizumab plus chemotherapy alone. The preliminary OS improved to 19.2 months vs 14.4 months respectively (HR=0.775, P=0.0262; 95% CI=0.619-0.970).

Common atezolizumab-related side effects.

REFERENCES

1. Prescribing information pembrolizumab (Keytruda®), revised: 11/2017
2. Langer, CJ et al. Lancet Oncol 2016;17(11):1497-1508
3. Merck Press Release KEYNOTE-189, accessed 26 March 2018
4. Prescribing information durvalumab (Imfinzi®), revised: 02/2018
5. Antonia SJ et al. N Engl J Med. 2017;377(20):1919-29
6. BMS Press Release CheckMate-227, accessed 26 March 2018
7. Prescribing information nivolumab (Opdivo®), revised: 02/2018
8. Roche Press Release IMpower-131, accessed 26 March 2018
9. Reck M et al. Ann Oncol 2017;28(S11):xi31
10. Prescribing information atezolizumab (Tecentriq®), revised: 04/2017

Disclaimer

This article is not medical advice. Patients should seek personal assessment by a licenced specialist. Physicians are recommended to read the full publication(s) as cited in the article before making medical decisions. This article does not supersede nor replace the published article(s).

© Copyright 2018 MediPaper Medical Communications Ltd. – Making sense of immunotherapy for non-small cell lung cancer (NSCLC)

Share this entry
  • Share on Facebook
  • Share on Twitter
  • Share on WhatsApp
  • Share on Pinterest
  • Share on LinkedIn
  • Share by Mail

YOU MAY ALSO LIKE

the-evolving-role-of-nk1-in-cinv-management-chemotherapy-induced-nausea-vomiting-akynzeo-nepa-palonosetron-netupitant

The evolving role of NK1 in CINV management

https://medi-paper.com/wp-content/uploads/2021/04/the-evolving-role-of-nk1-in-cinv-management-chemotherapy-induced-nausea-vomiting-akynzeo-nepa-palonosetron-netupitant-e1618546071115.jpg 1024 1917 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2021-04-16 09:17:092021-04-20 13:49:08The evolving role of NK1 in CINV management
Lung Cancer Update April 2021

Lung Cancer Update April 2021

https://medi-paper.com/wp-content/uploads/2021/04/Lung-Cancer-Update-April-2021.jpg 1000 1500 Kirsty LEE https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Kirsty LEE2021-04-08 16:28:082021-04-16 10:06:17Lung Cancer Update April 2021
Abemaciclib A review of the evidence through clinical case

Abemaciclib: A review of the evidence through clinical cases

https://medi-paper.com/wp-content/uploads/2021/03/Abemaciclib-A-review-of-the-evidence-through-clinical-case.jpg 1000 1500 Kirsty LEE https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Kirsty LEE2021-03-25 15:09:132021-04-20 13:51:14Abemaciclib: A review of the evidence through clinical cases
The Role of Patient Blood Management for Inflammatory Bowel Disease-01

The Role of Patient Blood Management for Inflammatory Bowel Disease

https://medi-paper.com/wp-content/uploads/2021/02/The-Role-of-Patient-Blood-Management-for-Inflammatory-Bowel-Disease-01.png 1024 1917 Kirsty LEE https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Kirsty LEE2021-02-27 19:09:322021-03-02 17:48:41The Role of Patient Blood Management for Inflammatory Bowel Disease
COVID-19 impacting regular patient care for cardiovascular diseases

COVID-19 impacting regular patient care for cardiovascular diseases

https://medi-paper.com/wp-content/uploads/2021/02/COVID-19-impacting-regular-patient-care-for-cardiovascular-diseases.jpg 1024 1918 Kirsty LEE https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Kirsty LEE2021-02-17 11:52:282021-03-02 17:48:19COVID-19 impacting regular patient care for cardiovascular diseases
SARS-CoV-2 infection in children and an increased risk of thrombotic microangiopathy

SARS-CoV-2 infection in children and an increased risk of thrombotic microangiopathy

https://medi-paper.com/wp-content/uploads/2021/02/SARS-CoV-2-infection-in-children-and-an-increased-risk-of-thrombotic-microangiopathy.jpg 1024 1918 Kirsty LEE https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Kirsty LEE2021-02-10 15:41:562021-03-02 17:48:11SARS-CoV-2 infection in children and an increased risk of thrombotic microangiopathy
Registry data shows early and large LDL reductions are associated with lowest post-MI cardiovascular event rates

Registry data shows early and large LDL reductions are associated with lowest post-MI cardiovascular event rates

https://medi-paper.com/wp-content/uploads/2021/02/Registry-data-shows-early-and-large-LDL-reductions-are-associated-with-lowest-post-MI-cardiovascular-event-rates.jpg 1024 1918 Kirsty LEE https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Kirsty LEE2021-02-10 10:35:042021-03-02 17:48:07Registry data shows early and large LDL reductions are associated with lowest post-MI cardiovascular event rates
Breast-Cancer-Update-2021

Breast cancer update January 2021

https://medi-paper.com/wp-content/uploads/2021/01/Breast-Cancer-Update-2021.jpg 1024 1918 Kirsty LEE https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Kirsty LEE2021-02-01 16:44:392021-02-02 14:55:17Breast cancer update January 2021
Osimertinib approved as the first adjuvant treatment for early non-small cell lung cancer

Osimertinib approved as the first adjuvant treatment for early non-small cell lung cancer

https://medi-paper.com/wp-content/uploads/2021/01/Osimertinib-approved-as-the-first-adjuvant-treatment-for-early-non-small-cell-lung-cancer.jpg 1024 1918 Kirsty LEE https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Kirsty LEE2021-01-28 11:43:032021-02-02 14:56:44Osimertinib approved as the first adjuvant treatment for early non-small cell lung cancer
Increasing dose frequency of lanreotide autogel injections in neuroendocrine tumours

Increasing dose frequency of lanreotide autogel injections in neuroendocrine tumours

https://medi-paper.com/wp-content/uploads/2021/01/Increasing-dose-frequency-of-lanreotide-autogel-injections-in-neuroendocrine-tumours.jpg 1024 1918 Kirsty LEE https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Kirsty LEE2021-01-27 11:18:282021-02-02 09:00:43Increasing dose frequency of lanreotide autogel injections in neuroendocrine tumours
cabotegravir-and-rilpivirine-intramuscular-combination-safe-in-women

Cabotegravir and rilpivirine intramuscular combination safe in women

https://medi-paper.com/wp-content/uploads/2020/12/cabotegravir-and-rilpivirine-intramuscular-combination-safe-in-women.jpg 1024 1819 Kirsty LEE https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Kirsty LEE2020-12-11 16:25:172021-03-02 17:51:19Cabotegravir and rilpivirine intramuscular combination safe in women
hcv-infected-kidneys-safe-for-transplantation-with-antiviral-treatment

HCV-infected kidneys safe for transplantation with antiviral treatment

https://medi-paper.com/wp-content/uploads/2020/12/hcv-infected-kidneys-safe-for-transplantation-with-antiviral-treatment.jpg 1024 1819 Kirsty LEE https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Kirsty LEE2020-12-11 15:46:392021-03-02 17:51:24HCV-infected kidneys safe for transplantation with antiviral treatment
baloxavir-marboxil-recommended-as-post-exposure-prophylaxis-to-influenza-by-ema

Baloxavir marboxil recommended as post-exposure prophylaxis to influenza by EMA

https://medi-paper.com/wp-content/uploads/2020/12/baloxavir-marboxil-recommended-as-post-exposure-prophylaxis-to-influenza-by-ema.jpg 1024 1819 Kirsty LEE https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Kirsty LEE2020-12-11 12:11:172021-03-02 17:51:13Baloxavir marboxil recommended as post-exposure prophylaxis to influenza by EMA
U.S. FDA approved immunecheckpoint inhibitors U.S. FDA approved immunotherapies for cancer U.S. FDA approved immunotherapies for cancer

US FDA approved immune-checkpoint inhibitors updated 08-Dec-2020

https://medi-paper.com/wp-content/uploads/2017/08/U.S.-FDA-approved-immunecheckpoint-inhibitors--e1528903094981.jpg 1194 1254 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2020-12-08 18:00:012020-12-10 20:19:55US FDA approved immune-checkpoint inhibitors updated 08-Dec-2020
detecting metastases with psma pet in prostate cancer

Detecting metastases with PSMA-PET in prostate cancer

https://medi-paper.com/wp-content/uploads/2020/12/detecting-metastases-with-psma-pet-in-prostate-cancer.jpg 1024 1819 Kirsty LEE https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Kirsty LEE2020-12-08 10:03:172020-12-11 15:12:41Detecting metastases with PSMA-PET in prostate cancer
asco guidelines for the use of systemic therapies in advanced hepatocellular cancer

ASCO Guidelines for the Use of Systemic Therapies in Advanced Hepatocellular Cancer

https://medi-paper.com/wp-content/uploads/2020/12/asco-guidelines-for-the-use-of-systemic-therapies-in-advanced-hepatocellular-cancer.jpg 1024 1819 Kirsty LEE https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Kirsty LEE2020-12-07 17:20:022020-12-11 14:24:21ASCO Guidelines for the Use of Systemic Therapies in Advanced Hepatocellular Cancer
Sotorasib for the treatment of KRASG12C-mutated lung cancer

Sotorasib for the treatment of KRASG12C mutated lung cancer

https://medi-paper.com/wp-content/uploads/2020/10/Sotorasib-for-the-treatment-of-KRASG12C-mutated-lung-cancer.jpg 1024 1819 Kirsty LEE https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Kirsty LEE2020-10-15 10:16:382020-10-15 11:45:13Sotorasib for the treatment of KRASG12C mutated lung cancer
Capmatinib therapy for the treatment of MET-positive non-small cell lung cancer

Capmatinib therapy for the treatment of MET-positive non-small cell lung cancer

https://medi-paper.com/wp-content/uploads/2020/10/Capmatinib-therapy-for-the-treatment-of-MET-positive-non-small-cell-lung-cancer.jpg 1024 1819 Kirsty LEE https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Kirsty LEE2020-10-15 09:46:042020-10-15 11:41:25Capmatinib therapy for the treatment of MET-positive non-small cell lung cancer
data-for-safe-and-effective-use-of-evolocumab-in-paediatric-familial-hypercholesterolaemia

Data for safe and effective use of evolocumab in paediatric familial hypercholesterolaemia

https://medi-paper.com/wp-content/uploads/2020/10/data-for-safe-and-effective-use-of-evolocumab-in-paediatric-familial-hypercholesterolaemia.jpg 1024 1819 Kirsty LEE https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Kirsty LEE2020-10-08 16:12:402020-10-12 16:01:55Data for safe and effective use of evolocumab in paediatric familial hypercholesterolaemia
psoriasis-biologics-may-help-reduce-coronary-plaque

Psoriasis biologics may help reduce coronary plaque

https://medi-paper.com/wp-content/uploads/2020/10/psoriasis-biologics-may-help-reduce-coronary-plaque.jpg 1024 1819 Kirsty LEE https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Kirsty LEE2020-10-08 15:45:112020-10-12 17:55:31Psoriasis biologics may help reduce coronary plaque
ticagrelor-may-not-confer-post-mi-benefits-to-elderly-patients

Ticagrelor may not confer post-MI benefits to elderly patients

https://medi-paper.com/wp-content/uploads/2020/10/ticagrelor-may-not-confer-post-mi-benefits-to-elderly-patients.jpg 1024 1819 Kirsty LEE https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Kirsty LEE2020-10-08 15:05:532020-10-12 16:00:51Ticagrelor may not confer post-MI benefits to elderly patients
Evidence-of-SARS-CoV2-in-heart-cells

Evidence of SARS-CoV2 in heart cells

https://medi-paper.com/wp-content/uploads/2020/09/Evidence-of-SARS-CoV2-in-heart-cells.jpg 1024 1819 Kirsty LEE https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Kirsty LEE2020-09-22 10:19:272020-09-24 12:33:04Evidence of SARS-CoV2 in heart cells
Selpercatinib-displays-efficacy-in-RET -fusion-positive-non-small-cell-lung-cancer

Selpercatinib displays efficacy in RET fusion-positive non-small cell lung cancer

https://medi-paper.com/wp-content/uploads/2020/09/Selpercatinib-displays-efficacy-in-RET-fusion-positive-non-small-cell-lung-cancer-scaled.jpg 1024 1819 Kirsty LEE https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Kirsty LEE2020-09-07 21:04:252020-09-07 23:03:18Selpercatinib displays efficacy in RET fusion-positive non-small cell lung cancer

First liquid biopsy for NSCLC to receive FDA approval

https://medi-paper.com/wp-content/uploads/2020/09/First-liquid-biopsy-for-NSCLC-to-receive-FDA-approval-scaled.jpg 1024 1819 Kirsty LEE https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Kirsty LEE2020-09-07 10:09:062020-09-08 09:56:03First liquid biopsy for NSCLC to receive FDA approval
ESMO-releases-the-first-guideline-on-NGS-testing- in-cancers

ESMO releases the first guideline on NGS testing in cancers

https://medi-paper.com/wp-content/uploads/2020/09/ESMO-releases-the-first-guideline-on-NGS-testing-in-cancers-scaled.jpg 1024 1819 Kirsty LEE https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Kirsty LEE2020-09-07 09:36:352020-09-08 08:52:38ESMO releases the first guideline on NGS testing in cancers
risk-of-thrombosis-with-sars-cov-2-infection

Risk of thrombosis with SARS-CoV-2 infection

https://medi-paper.com/wp-content/uploads/2020/08/risk-of-thrombosis-with-sars-cov-2-infection-scaled.jpg 1024 1819 Kirsty LEE https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Kirsty LEE2020-08-27 16:33:072020-09-24 12:37:30Risk of thrombosis with SARS-CoV-2 infection
further-analyses-of-dapa-hf-shows-dapagliflozin-leads-to-fewer-outpatient-heart-failure

Class effect of SGLT2 inhibitors on heart failure reduction solidified with dapagliflozin and empagliflozin results

https://medi-paper.com/wp-content/uploads/2020/08/further-analyses-of-dapa-hf-shows-dapagliflozin-leads-to-fewer-outpatient-heart-failure-scaled.jpg 1024 1818 Kirsty LEE https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Kirsty LEE2020-08-25 14:40:232020-09-01 17:02:10Class effect of SGLT2 inhibitors on heart failure reduction solidified with dapagliflozin and empagliflozin results
residual-risk-of-hepatocellular-carcinoma-in-older-hepatitis-c-patients-even-after-viral-clearance

Residual risk of hepatocellular carcinoma in older Hepatitis C patients even after viral clearance

https://medi-paper.com/wp-content/uploads/2020/08/residual-risk-of-hepatocellular-carcinoma-in-older-hepatitis-c-patients-even-after-viral-clearance-scaled.jpg 1024 1819 Kirsty LEE https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Kirsty LEE2020-08-13 16:18:002020-08-17 16:56:12Residual risk of hepatocellular carcinoma in older Hepatitis C patients even after viral clearance
potential-protective-effects-of-the-influenza-vaccine-on-cardiovascular-outcomes-in-high-risk-populations

Potential protective effects of the influenza vaccine on cardiovascular outcomes in high-risk populations

https://medi-paper.com/wp-content/uploads/2020/08/potential-protective-effects-of-the-influenza-vaccine-on-cardiovascular-outcomes-in-high-risk-populations-scaled.jpg 1024 1819 Kirsty LEE https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Kirsty LEE2020-08-13 15:28:132020-08-17 16:56:09Potential protective effects of the influenza vaccine on cardiovascular outcomes in high-risk populations
updated-human-papillomavirus-vaccination-and-testing-recommendations-from-the-american-cancer-society

Updated human papillomavirus vaccination and testing recommendations from the American Cancer Society

https://medi-paper.com/wp-content/uploads/2020/08/updated-human-papillomavirus-vaccination-and-testing-recommendations-from-the-american-cancer-society-scaled.jpg 1024 1819 Kirsty LEE https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Kirsty LEE2020-08-13 14:41:322020-08-25 14:37:07Updated human papillomavirus vaccination and testing recommendations from the American Cancer Society
Lower-risk-MDS-patients-benefit-from-novel-drug-imetelstat

Lower-risk MDS patients benefit from novel drug, imetelstat

https://medi-paper.com/wp-content/uploads/2020/07/Lower-risk-MDS-patients-benefit-from-novel-drug-imetelstat.jpg 844 1500 Kirsty LEE https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Kirsty LEE2020-07-10 17:24:512020-08-11 09:56:13Lower-risk MDS patients benefit from novel drug, imetelstat
Carboplatin plus paclitaxel to be the new standard of care for anal cancer

Carboplatin plus paclitaxel to be the new standard of care for anal cancer

https://medi-paper.com/wp-content/uploads/2020/07/Carboplatin-plus-paclitaxel-to-be-the-new-standard-of-care-for-anal-cancer.jpg 1024 1819 Kirsty LEE https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Kirsty LEE2020-07-10 17:24:482020-08-11 09:52:36Carboplatin plus paclitaxel to be the new standard of care for anal cancer
ASCO 2020 ASCO20 virtual meeting NSCLC SCLC lung cancer breast cancer hepatocellular cancer HCC colorectal cancer CRC

ASCO 2020 Lung, Breast, and Liver Cancer Update

https://medi-paper.com/wp-content/uploads/2020/06/ASCO-2020-ASCO20-virtual-meeting-NSCLC-SCLC-lung-cancer-breast-cancer-hepatocellular-cancer-HCC-colorectal-cancer-CRC-e1593749874717.jpg 794 1500 Kirsty LEE https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Kirsty LEE2020-06-30 09:37:482020-09-24 12:33:53ASCO 2020 Lung, Breast, and Liver Cancer Update
Gastric Cancer ramucirumab cyramza pembrolizumab keytruda trastuzumab herceptin dMMR MSI HER2 VEGF VEGFR gastric adenocarcinoma GEJ gastroesophageal junction cancer

Second-line treatment of gastric cancer or cancer of the gastroesophegeal junction: a case study of ramucirumab in Hong Kong

https://medi-paper.com/wp-content/uploads/2020/04/gastric-adenocarcinoma-ramucirumab-cyramza-pembrolizumab-nivolumab-trastuzumab-dmmr-msi-her2-vegf-vegfr-gastric-cancer-gej-gastroesophageal-junction-cancer-pd-1-pd-l1-eli-lilly-lilly.png 850 1500 陳穎樂醫生 https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png 陳穎樂醫生2020-04-30 14:03:452021-03-02 17:50:45Second-line treatment of gastric cancer or cancer of the gastroesophegeal junction: a case study of ramucirumab in Hong Kong
Capivasertib added to fulvestrant improves progression-free survival in advanced breast cancer patients

Capivasertib added to fulvestrant improves progression-free survival in advanced breast cancer patients

https://medi-paper.com/wp-content/uploads/2020/02/Capivasertib-added-to-fulvestrant-improves-progression-free-survival-in-advanced-breast-cancer-patients.jpg 1000 1500 Christy HC CHEUNG, BSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Christy HC CHEUNG, BSc2020-02-19 23:37:222020-02-21 10:24:39Capivasertib added to fulvestrant improves progression-free survival in advanced breast cancer patients
Capivasertib combined with paclitaxel improves survival of metastatic triple-negative breast cancer patients

Capivasertib plus paclitaxel improves survival of metastatic triple-negative breast cancer patients

https://medi-paper.com/wp-content/uploads/2019/12/Capivasertib-combined-with-paclitaxel-improves-survival-of-metastatic-triple-negative-breast-cancer-patients-e1582170747234.jpg 1000 1500 Christy HC CHEUNG, BSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Christy HC CHEUNG, BSc2020-02-11 17:30:382020-02-11 23:17:00Capivasertib plus paclitaxel improves survival of metastatic triple-negative breast cancer patients
Olaparib plus Bevacizumab as Maintenance Therapy in Ovarian Cancer

Olaparib plus Bevacizumab as Maintenance Therapy in Ovarian Cancer

https://medi-paper.com/wp-content/uploads/2019/12/Olaparib-plus-Bevacizumab-as-Maintenance-Therapy-in-Ovarian-Cancer.jpg 844 1500 Christy HC CHEUNG, BSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Christy HC CHEUNG, BSc2020-01-24 16:32:552020-01-24 16:40:07Olaparib plus Bevacizumab as Maintenance Therapy in Ovarian Cancer
ADDING RIBOCICLIB TO FULVESTRANT IMPROVES THE SURVIVAL OF ADVANCED BREAST CANCER PATIENTS MONALEESA-3

Ribociclib plus Fulvestrant Improves Survival in Advanced Breast Cancer

https://medi-paper.com/wp-content/uploads/2020/01/ADDING-RIBOCICLIB-TO-FULVESTRANT-IMPROVES-THE-SURVIVAL-OF-ADVANCED-BREAST-CANCER-PATIENTS-MONALEESA-3-scaled.jpg 1056 1500 Christy HC CHEUNG, BSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Christy HC CHEUNG, BSc2020-01-12 23:33:152020-01-13 10:41:47Ribociclib plus Fulvestrant Improves Survival in Advanced Breast Cancer
Somazina citicoline small vessel disease vascular cognitive impairment traumatic brain injury neuroimaging cerebrovascular disorders ischaemic haemorraghic stroke rehabilitation neuroprotection

Highlights of the 8th Asia Pacific Symposium on Cerebrovascular Disease

https://medi-paper.com/wp-content/uploads/2019/12/Somazina-citicoline-small-vessel-disease-vascular-cognitive-impairment-traumatic-brain-injury-neuroimaging-cerebrovascular-disorders-ischaemic-haemorraghic-stroke-rehabilitation-neuroprotection.png 1000 1500 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2019-12-16 10:35:082020-04-21 11:36:03Highlights of the 8th Asia Pacific Symposium on Cerebrovascular Disease
ASCO 2019 lung cancer NSCLC ASCO19 SCLC mesothelioma KEYNOTE-189 KEYNOTE-001 IMpower150 MYSTIC LCMC3 Lung-MAP S1400G S1400I Flaura CALGB 30901 DETERRED COMPASS

ASCO 2019 Lung Cancer: 36 Oral Presentations of the ASCO19 lung cancer track summarised

https://medi-paper.com/wp-content/uploads/2019/06/ASCO-2019-lung-cancer-NSCLC-ASCO19-SCLC-mesothelioma-KEYNOTE-189-KEYNOTE-001-IMpower150-MYSTIC-LCMC3-Lung-MAP-S1400G-S1400I-Flaura-CALGB-30901-DETERRED-COMPASS-.png 1000 750 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2019-06-12 14:12:322019-06-12 16:51:35ASCO 2019 Lung Cancer: 36 Oral Presentations of the ASCO19 lung cancer track summarised
paclitaxel, cobimetinib, Cotellic, MEK, Exelixis, atezolizumab, Tecentriq, nab-paclitaxel pembrolizumab, Keytruda, Merck, MSD, eribulin mesylate, Halaven, pertuzumab, trastuzumab, Herceptin, Perjeta, docetaxel, Taxotere, Sanofi, trastuzumab-dkst, Ogivri, Mylan, Biocon, margetuximab, MacroGenics, capecitabine, Xeloda, Genentech, gemcitabine, Gemzar, vinolrebine, pyrotinib, Jiangsu HengRui Medicine, neratinib, Nerlynx, Puma, lapatinib, Tykerb, carboplatin, T-DM1, ado-trastuzumab emtansine, Kadcyla doxorubicin, cisplatin, olaparib, Lynparza, cyclophosphamide, epirubicin, Ellence, Pharmorubicin, letrozole, Femara, Novartis, AI, NSAI, capivasertib, capivasertib, AZD5363, AKT, hormonal therapy, endocrine therapy, CDK4/6, RAD001, mTOR, fulvestrant, Faslodex, abemaciclib, Verzenio, Eli Lilly, ribociclib, Kisqali, goserilin, Zoladex, AstraZeneca, everolimus, Afinitor, exemestane, Aromasin, Pfizer, palbociclib, Ibrance, #ASCO2019, AKT1, AZ, BRCA, chemotherapy, CNS metastases, ER-positive, ESR1, GnRH, HER2-negative, HER2-positive, HR-positive, LABC, neoadjuvant, OfS, PARP, PARPi, pCR, PD-L1, postmenopausal, PR-positive, premenopausal, RB1, TAC, taxane, TNBC, trastuzumab, triptorelin

ASCO 2019 Breast Cancer: The ASCO19 breast cancer track summarised

https://medi-paper.com/wp-content/uploads/2019/05/ASCO-2019-breast-cancer-TNBC-MBC-ABC-ASCO19-MONALEESA-7-TRINITI-1-FAKTION-TBCRC030-NeoSTOP-ETNA-GeparOLA-KRISTINE-PREDIX-CLEOPATRA-HERITAGE-SOPHIA-NALA-IMpassion-130-Tapur-Colet.jpg 1000 1500 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2019-06-03 16:53:572019-06-04 14:34:55ASCO 2019 Breast Cancer: The ASCO19 breast cancer track summarised

Venetoclax FDA approved for CLL and SLL

https://medi-paper.com/wp-content/uploads/2018/11/1542721242_FDA-Logo-2018-MediPR-Medi-Paper-MediPaper-Medical-Communications-Ltd.-.png 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2019-05-15 16:19:292019-05-23 12:36:08Venetoclax FDA approved for CLL and SLL

FDA approves avelumab plus axitinib for renal cell carcinoma

https://medi-paper.com/wp-content/uploads/2018/11/1542721242_FDA-Logo-2018-MediPR-Medi-Paper-MediPaper-Medical-Communications-Ltd.-.png 1000 1495 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2019-05-14 16:22:572019-05-22 22:49:14FDA approves avelumab plus axitinib for renal cell carcinoma

Ramucirumab FDA approved for hepatocellular carcinoma

https://medi-paper.com/wp-content/uploads/2018/11/1542721242_FDA-Logo-2018-MediPR-Medi-Paper-MediPaper-Medical-Communications-Ltd.-.png 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2019-05-10 16:24:042019-05-23 11:58:38Ramucirumab FDA approved for hepatocellular carcinoma

T-DM1 FDA approved for early breast cancer

https://medi-paper.com/wp-content/uploads/2018/11/1542721242_FDA-Logo-2018-MediPR-Medi-Paper-MediPaper-Medical-Communications-Ltd.-.png 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2019-05-03 16:24:342019-05-22 22:14:15T-DM1 FDA approved for early breast cancer

Ivosidenib FDA-approved as first-line treatment for AML patients with IDH1 mutation

https://medi-paper.com/wp-content/uploads/2018/11/1542721242_FDA-Logo-2018-MediPR-Medi-Paper-MediPaper-Medical-Communications-Ltd.-.png 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2019-05-02 16:25:032019-05-22 22:14:36Ivosidenib FDA-approved as first-line treatment for AML patients with IDH1 mutation
Can a novel, temporary, and fully resorbable surgical implant improve the outcome of common hockey and soccer injuries?

Can a novel, temporary, and fully resorbable surgical implant improve the outcome of common hockey and soccer injuries?

https://medi-paper.com/wp-content/uploads/2019/04/Can-a-novel-temporary-and-fully-resorbable-surgical-implant-improve-the-outcome-of-common-hockey-and-soccer-injuries.jpg 1000 1500 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2019-04-26 20:05:262019-04-26 20:12:32Can a novel, temporary, and fully resorbable surgical implant improve the outcome of common hockey and soccer injuries?

Pembrolizumab plus axitinib FDA approved for the first-line treatment of advanced renal cell carcinoma patients

https://medi-paper.com/wp-content/uploads/2018/11/1542721242_FDA-Logo-2018-MediPR-Medi-Paper-MediPaper-Medical-Communications-Ltd.-.png 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2019-04-26 00:34:542019-04-26 00:38:58Pembrolizumab plus axitinib FDA approved for the first-line treatment of advanced renal cell carcinoma patients
KEYNOTE-158 pembrolizumab in previously treated advanced cervical cancer

KEYNOTE-158: pembrolizumab in previously treated advanced cervical cancer

https://medi-paper.com/wp-content/uploads/2019/04/KEYNOTE-158-pembrolizumab-in-previously-treated-advanced-cervical-cancer.jpg 844 1500 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2019-04-24 18:22:142019-04-24 18:22:14KEYNOTE-158: pembrolizumab in previously treated advanced cervical cancer
Atezolizumab with or without cobimetinib vs regorafenib for previously treated metastatic colorectal cancer IMblaze370

Atezolizumab +/- cobimetinib vs regorafenib for previously treated metastatic colorectal cancer (IMblaze370)

https://medi-paper.com/wp-content/uploads/2019/04/Atezolizumab-with-or-without-cobimetinib-vs-regorafenib-for-previously-treated-metastatic-colorectal-cancer-IMblaze370.jpg 1000 1500 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2019-04-22 21:21:372019-04-22 21:57:04Atezolizumab +/- cobimetinib vs regorafenib for previously treated metastatic colorectal cancer (IMblaze370)

Palbociclib approved for the treatment of male breast cancer 

https://medi-paper.com/wp-content/uploads/2018/11/1542721242_FDA-Logo-2018-MediPR-Medi-Paper-MediPaper-Medical-Communications-Ltd.-.png 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2019-04-22 16:13:232019-04-22 21:56:34Palbociclib approved for the treatment of male breast cancer 

Erdafitinib FDA approved for the treatment of metastatic urothelial carcinoma

https://medi-paper.com/wp-content/uploads/2018/11/1542721242_FDA-Logo-2018-MediPR-Medi-Paper-MediPaper-Medical-Communications-Ltd.-.png 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2019-04-22 14:35:132019-04-22 21:56:48Erdafitinib FDA approved for the treatment of metastatic urothelial carcinoma

Atezolizumab FDA approved for extensive-stage small cell lung cancer (SCLC)

https://medi-paper.com/wp-content/uploads/2018/11/1542721242_FDA-Logo-2018-MediPR-Medi-Paper-MediPaper-Medical-Communications-Ltd.-.png 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2019-03-23 09:39:402019-03-23 09:41:21Atezolizumab FDA approved for extensive-stage small cell lung cancer (SCLC)

Atezolizumab FDA approved for PD-L1 positive unresectable triple-negative breast cancer

https://medi-paper.com/wp-content/uploads/2018/11/1542721242_FDA-Logo-2018-MediPR-Medi-Paper-MediPaper-Medical-Communications-Ltd.-.png 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2019-03-09 23:15:272019-03-09 23:15:27Atezolizumab FDA approved for PD-L1 positive unresectable triple-negative breast cancer
Immunoncology I-O drugs and immunotherapy for renal cancer RCC

Combinations: upcoming treatment strategies in metastatic renal cell carcinoma

https://medi-paper.com/wp-content/uploads/2019/02/Immunoncology-I-O-drugs-and-immunotherapy-for-renal-cancer-RCC-.jpg 1000 1500 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2019-03-05 11:13:432019-03-07 14:27:09Combinations: upcoming treatment strategies in metastatic renal cell carcinoma

Trifluridine/tipiracil combination FDA approved for metastatic gastric or GEJ adenocarcinoma

https://medi-paper.com/wp-content/uploads/2018/11/1542721242_FDA-Logo-2018-MediPR-Medi-Paper-MediPaper-Medical-Communications-Ltd.-.png 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2019-02-23 15:05:352019-03-08 17:00:25Trifluridine/tipiracil combination FDA approved for metastatic gastric or GEJ adenocarcinoma

Pembrolizumab FDA approved for adjuvant treatment of melanoma

https://medi-paper.com/wp-content/uploads/2018/11/1542721242_FDA-Logo-2018-MediPR-Medi-Paper-MediPaper-Medical-Communications-Ltd.-.png 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2019-02-16 14:55:172019-03-07 14:56:16Pembrolizumab FDA approved for adjuvant treatment of melanoma

Trastuzumab-biosimilar Ontruzant® FDA approved in several indications

https://medi-paper.com/wp-content/uploads/2018/11/1542721242_FDA-Logo-2018-MediPR-Medi-Paper-MediPaper-Medical-Communications-Ltd.-.png 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2019-01-21 23:16:452019-04-22 16:24:29Trastuzumab-biosimilar Ontruzant® FDA approved in several indications
ERAS guidelines for antenatal and preoperative care in caesarean delivery 1

ERAS guidelines for antenatal and preoperative care in caesarean delivery

https://medi-paper.com/wp-content/uploads/2019/01/ERAS-guidelines-for-antenatal-and-preoperative-care-in-caesarean-delivery-1.jpg 814 1500 Anaesthesiology.asia https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Anaesthesiology.asia2019-01-21 13:54:592019-01-21 22:02:18ERAS guidelines for antenatal and preoperative care in caesarean delivery

Cabozantinib FDA approved in HCC patients failing sorafenib

https://medi-paper.com/wp-content/uploads/2018/11/FDA-Logo-2018-MediPR-Medi-Paper-MediPaper-Medical-Communications-Ltd.-.png 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2019-01-17 10:35:362019-02-18 13:23:29Cabozantinib FDA approved in HCC patients failing sorafenib
Erasmus University MC investigating a new surgical matrix to reduce post-operative complications

Erasmus University MC investigating a new surgical matrix to reduce post-operative complications

https://medi-paper.com/wp-content/uploads/2019/01/Erasmus-University-MC-investigating-a-new-surgical-matrix-to-reduce-post-operative-complications.jpg 900 1500 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2019-01-16 22:58:582019-01-16 23:09:21Erasmus University MC investigating a new surgical matrix to reduce post-operative complications

Keytruda® FDA approved for recurrent and metastatic Merkel cell carcinoma

https://medi-paper.com/wp-content/uploads/2018/11/1542721242_FDA-Logo-2018-MediPR-Medi-Paper-MediPaper-Medical-Communications-Ltd.-.png 1000 1495 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2019-01-14 15:36:172019-01-14 15:43:55Keytruda® FDA approved for recurrent and metastatic Merkel cell carcinoma

Calaspargase pegol-mknl (Asparlas®) FDA approved in paediatric and young adult acute lymphoblastic leukaemia (ALL) patients

https://medi-paper.com/wp-content/uploads/2018/11/1542721242_FDA-Logo-2018-MediPR-Medi-Paper-MediPaper-Medical-Communications-Ltd.-.png 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-12-27 16:16:402018-12-27 16:16:40Calaspargase pegol-mknl (Asparlas®) FDA approved in paediatric and young adult acute lymphoblastic leukaemia (ALL) patients

Elzonris™ FDA approved for blastic plasmacytoid dendritic cell neoplasm (BPDCN)

https://medi-paper.com/wp-content/uploads/2018/11/1542721242_FDA-Logo-2018-MediPR-Medi-Paper-MediPaper-Medical-Communications-Ltd.-.png 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-12-27 15:51:482018-12-27 15:53:57Elzonris™ FDA approved for blastic plasmacytoid dendritic cell neoplasm (BPDCN)
Dr Paul Kessler - Euroanaesthesia 2018 - Awake, Sedated or Anaesthetised for Regional Anaesthesia Block Placements©Aspen Pharmacare

Awake, Sedated or Anaesthetised for Regional Anaesthesia Block Placements

https://medi-paper.com/wp-content/uploads/2018/12/Dr-Paul-Kessler-Euroanaesthesia-2018-Awake-Sedated-or-Anaesthetised-for-Regional-Anaesthesia-Block-Placements.png 539 800 Anaesthesiology.asia https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Anaesthesiology.asia2018-12-26 16:49:292019-01-23 13:34:18Awake, Sedated or Anaesthetised for Regional Anaesthesia Block Placements
Dr Ngai LIU - Euroanaesthesia 2018 - Closed-Loop or Automated Titration of IV Anaesthesia Impact on Routine Anaesthesia©Aspen Pharmacare

Closed-Loop or Automated Titration of IV Anaesthesia: Impact on Routine Anaesthesia

https://medi-paper.com/wp-content/uploads/2018/12/Dr-Ngai-LIU-Euroanaesthesia-2018-Closed-Loop-or-Automated-Titration-of-IV-Anaesthesia-Impact-on-Routine-Anaesthesia-e1548221779756.png 444 800 Anaesthesiology.asia https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Anaesthesiology.asia2018-12-25 00:45:102019-01-23 13:33:53Closed-Loop or Automated Titration of IV Anaesthesia: Impact on Routine Anaesthesia

Olaparib (Lynparza) FDA approved as maintenance for BRCAm ovarian cancer

https://medi-paper.com/wp-content/uploads/2018/11/1542721242_FDA-Logo-2018-MediPR-Medi-Paper-MediPaper-Medical-Communications-Ltd.-.png 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-12-22 16:54:192018-12-22 16:54:19Olaparib (Lynparza) FDA approved as maintenance for BRCAm ovarian cancer

Trastuzumab-biosimilar Herzuma® FDA approved in HER2+ breast cancer

https://medi-paper.com/wp-content/uploads/2018/11/1542721242_FDA-Logo-2018-MediPR-Medi-Paper-MediPaper-Medical-Communications-Ltd.-.png 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-12-21 15:19:112018-12-21 15:32:40Trastuzumab-biosimilar Herzuma® FDA approved in HER2+ breast cancer

Frontline atezolizumab plus bevacizumab and chemotherapy FDA approved for metastatic non-squamous NSCLC

https://medi-paper.com/wp-content/uploads/2018/11/1542721242_FDA-Logo-2018-MediPR-Medi-Paper-MediPaper-Medical-Communications-Ltd.-.png 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-12-11 13:21:272018-12-11 13:22:23Frontline atezolizumab plus bevacizumab and chemotherapy FDA approved for metastatic non-squamous NSCLC
MURANO: off-drug progression-free survival after 2 years venetoclax plus 6 cycles Rituximab

MURANO: off-drug progression-free survival after 2 years venetoclax plus 6 cycles Rituximab

https://medi-paper.com/wp-content/uploads/2018/12/Depositphotos_159314198_xl-2015.jpg 1000 1500 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-12-05 22:00:342018-12-13 13:22:27MURANO: off-drug progression-free survival after 2 years venetoclax plus 6 cycles Rituximab
TIGR®Matrix shows promising results when used for incisional hernia prevention in septic patients undergoing laparoscopy

TIGR®Matrix shows promising results when used for incisional hernia prevention in septic patients undergoing laparoscopy

https://medi-paper.com/wp-content/uploads/2018/12/TIGR®Matrix-shows-promising-results-when-used-for-incisional-hernia-prevention-in-septic-patients-undergoing-laparoscopy.jpg 1000 1500 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-12-04 21:28:362018-12-05 11:50:08TIGR®Matrix shows promising results when used for incisional hernia prevention in septic patients undergoing laparoscopy
Efficacy of Oral Cladribine in Multiple Sclerosis Durable after a 2-Year Course of Treatment

Efficacy of oral Cladribine for MS durable after a two-year treatment course

https://medi-paper.com/wp-content/uploads/2018/12/Efficacy-of-Oral-Cladribine-in-Multiple-Sclerosis-Durable-after-a-2-Year-Course-of-Treatment.jpg 1000 1500 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-12-03 17:05:442018-12-03 17:21:47Efficacy of oral Cladribine for MS durable after a two-year treatment course

Gilteritinib (Xospata®) FDA approved for relapsed or refractory AML harbouring FLT3 mutations

https://medi-paper.com/wp-content/uploads/2018/11/1542721242_FDA-Logo-2018-MediPR-Medi-Paper-MediPaper-Medical-Communications-Ltd.-.png 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-11-29 15:08:432018-11-29 15:11:38Gilteritinib (Xospata®) FDA approved for relapsed or refractory AML harbouring FLT3 mutations

TKR inhibitor larotrectinib (Vitrakvi®) FDA approved for cancers with NTRK gene fusion

https://medi-paper.com/wp-content/uploads/2018/11/1542721242_FDA-Logo-2018-MediPR-Medi-Paper-MediPaper-Medical-Communications-Ltd.-.png 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-11-28 17:00:152018-11-28 18:03:05TKR inhibitor larotrectinib (Vitrakvi®) FDA approved for cancers with NTRK gene fusion

FDA Approves Truxima as Biosimilar to Rituxan

https://medi-paper.com/wp-content/uploads/2018/11/FDA-Logo-2018-MediPR-Medi-Paper-MediPaper-Medical-Communications-Ltd.-.png 1000 1495 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2018-11-28 14:34:182019-11-12 15:16:57FDA Approves Truxima as Biosimilar to Rituxan
Meta-analysis TIVA with propofol lowers post-operative nausea, vomiting, and pain

Meta-analysis: TIVA with propofol lowers post-operative nausea, vomiting, and pain

https://medi-paper.com/wp-content/uploads/2018/11/Meta-analysis-TIVA-with-propofol-lowers-post-operative-nausea-vomiting-and-pain.jpg 861 1500 Anaesthesiology.asia https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Anaesthesiology.asia2018-11-27 15:43:582018-11-28 10:18:56Meta-analysis: TIVA with propofol lowers post-operative nausea, vomiting, and pain

Venetoclax plus azacitidine, decitabine, or low-dose cytarabine FDA approved in elderly AML patients

https://medi-paper.com/wp-content/uploads/2018/11/1542721242_FDA-Logo-2018-MediPR-Medi-Paper-MediPaper-Medical-Communications-Ltd.-.png 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-11-23 23:17:102018-11-23 23:24:03Venetoclax plus azacitidine, decitabine, or low-dose cytarabine FDA approved in elderly AML patients

Glasdegib plus low-dose cytarabine (LDAC) approved in elderly AML patients

https://medi-paper.com/wp-content/uploads/2018/11/1542721242_FDA-Logo-2018-MediPR-Medi-Paper-MediPaper-Medical-Communications-Ltd.-.png 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-11-23 22:43:422018-11-23 22:43:42Glasdegib plus low-dose cytarabine (LDAC) approved in elderly AML patients
Robert Lewandowski Y90 TARE TheraSphere The Emerging Role of Yttrium90 in Primary and Metastatic Liver Cancer hepatocellular carcinoma hcc

The Emerging Role of Yttrium-90 in Primary and Metastatic Liver Cancer

https://medi-paper.com/wp-content/uploads/2018/11/Y90-TARE-TheraSphere-The-Emerging-Role-of-Yttrium-90-in-Primary-and-Metastatic-Liver-Cancer..jpg 844 1500 Adrian YIP https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Adrian YIP2018-11-22 22:48:462018-12-11 10:42:29The Emerging Role of Yttrium-90 in Primary and Metastatic Liver Cancer
Intraperitoneal bupivacaine to reduce postoperative opioid-use following laparoscopic appendectomy©MediPaper Medical Communications Ltd

Intraperitoneal bupivacaine to reduce postoperative opioid-use following laparoscopic appendectomy

https://medi-paper.com/wp-content/uploads/2018/11/Intraperitoneal-bupivacaine-to-reduce-postoperative-opioid-use-following-laparoscopic-appendectomy.jpg 1000 1500 Anaesthesiology.asia https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Anaesthesiology.asia2018-11-22 12:43:272018-11-22 12:51:37Intraperitoneal bupivacaine to reduce postoperative opioid-use following laparoscopic appendectomy

Emapalumab FDA approved in adult and paediatric patients with primary hemophagocytic lymphohistiocytosis

https://medi-paper.com/wp-content/uploads/2018/11/1542721242_FDA-Logo-2018-MediPR-Medi-Paper-MediPaper-Medical-Communications-Ltd.-.png 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-11-21 23:38:102018-11-21 23:49:14Emapalumab FDA approved in adult and paediatric patients with primary hemophagocytic lymphohistiocytosis

Brentuximab vedotin (Adcetris®) plus chemotherapy approved for several CD30 expressing lymphomas

https://medi-paper.com/wp-content/uploads/2018/11/1542721242_FDA-Logo-2018-MediPR-Medi-Paper-MediPaper-Medical-Communications-Ltd.-.png 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-11-21 23:01:122018-11-21 23:05:07Brentuximab vedotin (Adcetris®) plus chemotherapy approved for several CD30 expressing lymphomas
Fully resorbable synthetic matrix offers improved safety for breast cancer patients undergoing immediate breast reconstruction

Fully resorbable synthetic matrix offers improved safety for breast cancer patients undergoing immediate breast reconstruction

https://medi-paper.com/wp-content/uploads/2018/11/Fully-resorbable-synthetic-matrix-offers-improved-safety-for-breast-cancer-patients-undergoing-immediate-breast-reconstruction.jpg 1000 1500 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-11-21 16:41:202018-12-04 21:34:06Fully resorbable synthetic matrix offers improved safety for breast cancer patients undergoing immediate breast reconstruction

Pembrolizumab FDA approved in hepatocellular carcinoma patients pretreated with sorafenib

https://medi-paper.com/wp-content/uploads/2018/10/1540992382_FDA-Logo-2018-MediPR-Medi-Paper-MediPaper-Medical-Communications-Ltd.-.png 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-11-19 11:11:132018-11-19 13:45:58Pembrolizumab FDA approved in hepatocellular carcinoma patients pretreated with sorafenib
Prof. Stephen Chan i-o-immunooncology-nivolumab-immunotherapy-hcv-hbv-reactivation-hepatitis-b-hepatitis-c-carrier

I-O in Special Populations: Chronic Viral Hepatitis Carriers

https://medi-paper.com/wp-content/uploads/2018/07/Prof.-Stephen-Chan-i-o-immunooncology-nivolumab-immunotherapy-hcv-hbv-reactivation-hepatitis-b-hepatitis-c-carrier.jpg 1000 1500 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2018-11-18 21:51:462018-12-17 14:08:24I-O in Special Populations: Chronic Viral Hepatitis Carriers

Lorlatinib FDA approved for metastatic ALK-positive NSCLC

https://medi-paper.com/wp-content/uploads/2018/10/1540992382_FDA-Logo-2018-MediPR-Medi-Paper-MediPaper-Medical-Communications-Ltd.-.png 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-11-06 11:30:052018-11-06 11:32:59Lorlatinib FDA approved for metastatic ALK-positive NSCLC
ESMO 2018 HCC ESMO18 Liver Cancer ESMO2018 hepatocellular carcinoma hepatobiliary cholangiocarcinoma BTC

ESMO 2018 HCC: The ESMO18 hepatobiliary cancer track summarised

https://medi-paper.com/wp-content/uploads/2018/10/esmo-2018-hcc-esmo18-liver-cancer-esmo-2018-hepatocellular-carcinoma-hepatobilliary-cholangiocarcinoma-btc-.png 1001 1500 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2018-11-03 17:30:562018-11-05 12:51:54ESMO 2018 HCC: The ESMO18 hepatobiliary cancer track summarised

Pembrolizumab plus chemotherapy approved for metastatic squamous NSCLC

https://medi-paper.com/wp-content/uploads/2018/10/1540992382_FDA-Logo-2018-MediPR-Medi-Paper-MediPaper-Medical-Communications-Ltd.-.png 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-11-01 10:49:132018-11-01 10:53:51Pembrolizumab plus chemotherapy approved for metastatic squamous NSCLC
Dr Joanne Chiu HKU management irAE hepatitis manage immune-mediated hepatitis immunotherapy I-O immunooncology immune-induced hepatitis

Management of Immune-Mediated Hepatitis: a Case Report

https://medi-paper.com/wp-content/uploads/2018/04/management-irAE-hepatitis-manage-immune-mediated-hepatitis-immunotherapy-I-O-immunooncology-immune-induced-hepatitis--e1542867473384.jpg 844 1500 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2018-10-31 05:53:132018-11-22 15:01:08Management of Immune-Mediated Hepatitis: a Case Report
Early treatment with ocrelizumab lowers 5-year brain atrophy-rates in MS

Early treatment with ocrelizumab lowers 5-year brain atrophy rates in MS

https://medi-paper.com/wp-content/uploads/2018/10/Early-treatment-with-ocrelizumab-lowers-5-year-brain-atrophy-rates-in-MS.jpg 1000 1500 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2018-10-25 17:57:002018-11-06 11:36:05Early treatment with ocrelizumab lowers 5-year brain atrophy rates in MS

PARPi talazoparib FDA approved for deleterious gBRCAm HER2‑negative breast cancer

https://medi-paper.com/wp-content/uploads/2018/10/1539706020_FDA-Logo-2018-MediPR-Medi-Paper-MediPaper-Medical-Communications-Ltd.-.png 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-10-18 20:50:302018-10-18 21:12:52PARPi talazoparib FDA approved for deleterious gBRCAm HER2‑negative breast cancer
innovent biologics anti-pd1 sintilimab plus biosimilar bevacizumab receive ind status by china nmpa

Anti-PD1 sintilimab plus biosimilar bevacizumab receive IND-status by China NMPA

https://medi-paper.com/wp-content/uploads/2018/10/innovent-biologics-anti-pd1-sintilimab-plus-biosimilar-bevacizumab-receive-ind-status-by-china-nmpa-e1539612467836.jpg 1000 1500 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-10-15 22:26:302018-10-17 11:29:45Anti-PD1 sintilimab plus biosimilar bevacizumab receive IND-status by China NMPA
IMpower133 first-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer

IMpower133: first-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer

https://medi-paper.com/wp-content/uploads/2018/10/IMpower133-first-line-atezolizumab-plus-chemotherapy-in-extensive-stage-small-cell-lung-cancer-e1539272789598.png 1000 1500 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-10-11 23:48:162018-10-17 11:29:19IMpower133: first-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer
Pembrolizumab plus chemotherapy effective in squamous NSCLC

Pembrolizumab plus chemotherapy effective in squamous NSCLC

https://medi-paper.com/wp-content/uploads/2018/10/Pembrolizumab-plus-chemotherapy-effective-in-squamous-NSCLC.jpg 1000 1500 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-10-08 00:43:132018-10-17 11:27:05Pembrolizumab plus chemotherapy effective in squamous NSCLC
Ipilimumab plus nivolumab for persistent or recurrent ovarian cancer

Ipilimumab plus nivolumab for persistent or recurrent ovarian cancer

https://medi-paper.com/wp-content/uploads/2018/10/Ipilimumab-plus-nivolumab-for-persistent-or-recurrent-ovarian-cancer.jpg 1000 1500 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-10-07 00:13:112018-10-17 11:26:28Ipilimumab plus nivolumab for persistent or recurrent ovarian cancer
Brigatinib prolongs PFS compared to crizotinib in ALK-Positive NSCLC

Brigatinib prolongs PFS compared to crizotinib in ALK-Positive NSCLC

https://medi-paper.com/wp-content/uploads/2018/10/Brigatinib-prolongs-PFS-compared-to-crizotinib-in-ALK-Positive-NSCLC.jpg 1000 1500 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-10-05 17:27:422018-10-17 11:25:12Brigatinib prolongs PFS compared to crizotinib in ALK-Positive NSCLC
CAR-T axicabtagene ciloleucel granted Orphan Drug Designation for B-Cell Lymphoma by the Japan MHLW

CAR-T axicabtagene ciloleucel granted Orphan Drug designation for B-Cell Lymphoma by the Japan MHLW

https://medi-paper.com/wp-content/uploads/2018/10/CAR-T-axicabtagene-ciloleucel-granted-Orphan-Drug-Designation-for-B-Cell-Lymphoma-by-the-Japan-MHLW.jpg 1000 1500 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-10-05 15:24:252018-10-17 11:23:17CAR-T axicabtagene ciloleucel granted Orphan Drug designation for B-Cell Lymphoma by the Japan MHLW

PD-1 mAB cemiplimab FDA approved for locally advanced and metastatic cutaneous squamous cell carcinoma (CSCC)

https://medi-paper.com/wp-content/uploads/2018/10/FDA-Logo-2018-MediPR-Medi-Paper-MediPaper-Medical-Communications-Ltd.-.png 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-10-03 12:53:562018-10-17 11:20:52PD-1 mAB cemiplimab FDA approved for locally advanced and metastatic cutaneous squamous cell carcinoma (CSCC)
JAVELIN Lung 200 avelumab vs docetaxel in patients with pretreated advanced non-small cell lung cancer NSCLC

JAVELIN Lung 200: avelumab vs docetaxel for pretreated NSCLC

https://medi-paper.com/wp-content/uploads/2018/10/JAVELIN-Lung-200-avelumab-vs-docetaxel-in-patients-with-pretreated-advanced-non-small-cell-lung-cancer-NSCLC.jpg 1000 1500 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-10-02 01:01:252018-10-17 11:18:32JAVELIN Lung 200: avelumab vs docetaxel for pretreated NSCLC

Dacomitinib FDA approved for the first-line treatment of metastatic EGFR-mutated NSCLC

https://medi-paper.com/wp-content/uploads/2018/09/FDA-Logo-2018-MediPR-Medi-Paper-MediPaper-Medical-Communications-Ltd.-.png 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-09-28 23:18:162018-10-17 11:17:46Dacomitinib FDA approved for the first-line treatment of metastatic EGFR-mutated NSCLC
TAVR transcatheter aortic valve replacement with Portico valve reduces severe aortic stenosis in real-world study PORTICO-1

Transcatheter aortic valve replacement reduces severe aortic stenosis in real-world study

https://medi-paper.com/wp-content/uploads/2018/09/TAVR-transcatheter-aortic-valve-replacement-with-Portico-valve-reduces-severe-aortic-stenosis-in-real-world-study-PORTICO-1-e1538119953610.jpg 1000 1500 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-09-28 15:23:462018-10-17 11:15:20Transcatheter aortic valve replacement reduces severe aortic stenosis in real-world study
TAVR vs SAVR - Transcatheter- vs surgical aortic valve replacement in high-risk patients 5-years survival

Transcatheter- vs surgical aortic valve replacement in high-risk patients: 5-years survival

https://medi-paper.com/wp-content/uploads/2018/09/TAVR-vs-SAVR-Transcatheter-vs-surgical-aortic-valve-replacement-in-high-risk-patients-5-years-survival.jpg 1000 1500 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-09-28 12:43:062018-10-17 11:13:32Transcatheter- vs surgical aortic valve replacement in high-risk patients: 5-years survival
MediPr medipr.org medi-paper.com MediNews Asia MediNews.asia MediNews.cn MediPaper Medical Communications Ltd Healthcare Writers Medical Writers Medical Writer Agency Hong Kong Medical Writing Services Solutions Quote 醫學寫作 香港 醫學作家香港©United States Food and Drug Agency US FDA

Duvelisib FDA approved for adult patients with R/R CLL or SLL

https://medi-paper.com/wp-content/uploads/2018/09/FDA-Logo-2018-MediPR-Medi-Paper-MediPaper-Medical-Communications-Ltd.--e1537925034955.png 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-09-25 17:33:572018-09-25 17:46:01Duvelisib FDA approved for adult patients with R/R CLL or SLL
MediPr medipr.org medi-paper.com MediNews Asia MediNews.asia MediNews.cn MediPaper Medical Communications Ltd Healthcare Writers Medical Writers Medical Writer Agency Hong Kong Medical Writing Services Solutions Quote 醫學寫作 香港 醫學作家香港©United States Food and Drug Agency US FDA

Duvelisib FDA approved for adult patients with R/R follicular lymphoma

https://medi-paper.com/wp-content/uploads/2018/09/FDA-Logo-2018-MediPR-Medi-Paper-MediPaper-Medical-Communications-Ltd.--e1537925034955.png 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-09-25 17:20:472018-09-25 17:36:29Duvelisib FDA approved for adult patients with R/R follicular lymphoma
Front-line atezolizumab plus chemotherapy improves PFS in NSCLC

Frontline atezolizumab plus chemotherapy improves PFS in NSCLC

https://medi-paper.com/wp-content/uploads/2018/09/Front-line-atezolizumab-plus-chemotherapy-improves-PFS-in-NSCLC.png 1000 1500 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-09-25 10:01:562018-09-25 10:11:35Frontline atezolizumab plus chemotherapy improves PFS in NSCLC
First-line osimertinib vs EGFR-TKI in Asian patients with advanced NSCLC

First-line osimertinib vs EGFR-TKI in Asian patients with advanced NSCLC

https://medi-paper.com/wp-content/uploads/2018/09/First-line-osimertinib-vs-EGFR-TKI-in-Asian-patients-with-advanced-NSCLC.jpg 1000 1500 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2018-09-24 13:24:282018-09-24 15:25:11First-line osimertinib vs EGFR-TKI in Asian patients with advanced NSCLC
Early breast cancer treatment in China remains conservative

Early breast cancer treatment in China remains conservative

https://medi-paper.com/wp-content/uploads/2018/09/Early-breast-cancer-treatment-in-China-remains-conservative.jpg 1000 1510 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-09-23 23:35:002018-09-23 23:39:31Early breast cancer treatment in China remains conservative
immuno-oncology I-O treatment for the irAE Rash©MediPaper Medical Communications Ltd

ImmunoOncology: Dr Oscar Chan on the treatment of irAE rash

https://medi-paper.com/wp-content/uploads/2018/06/immuno-oncology-I-O-treatment-for-the-irAE-Rash.png 786 752 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2018-09-21 01:15:492018-09-21 13:29:44ImmunoOncology: Dr Oscar Chan on the treatment of irAE rash
Prof Stefan Kasper on I-O in EXTREME-ineligible Head and Neck Cancer I-O in SCCHN with focus on EXTREME-ineligible Patients and the future directions of combination immunotherapy

Prof Stefan Kasper on I-O in EXTREME-ineligible SCCHN

https://medi-paper.com/wp-content/uploads/2018/02/Prof-Stefan-Kasper-on-I-O-in-EXTREME-ineligible-Head-and-Neck-Cancer-I-O-in-SCCHN-with-focus-on-EXTREME-ineligible-Patients-and-the-future-directions-of-combination-immunotherapy.jpg 924 1500 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2018-09-19 12:54:212018-09-21 14:01:09Prof Stefan Kasper on I-O in EXTREME-ineligible SCCHN

Anti-coagulation: impact on long-term mortality and early valve dysfunction

https://medi-paper.com/wp-content/uploads/2018/09/cv7.jpg 905 1280 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-09-19 10:30:462018-09-19 20:45:35Anti-coagulation: impact on long-term mortality and early valve dysfunction
Camrelizumab anti-PD-1 with or without Chemotherapy for NPC

Camrelizumab anti-PD-1 with or without chemotherapy for NPC

https://medi-paper.com/wp-content/uploads/2018/09/Camrelizumab-anti-PD-1-with-or-without-Chemotherapy-for-NPC-e1537238880148.png 1000 1500 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-09-18 09:52:592018-09-18 09:55:32Camrelizumab anti-PD-1 with or without chemotherapy for NPC
MediPr medipr.org medi-paper.com MediNews Asia MediNews.asia MediNews.cn MediPaper Medical Communications Ltd Healthcare Writers Medical Writers Medical Writer Agency Hong Kong Medical Writing Services Solutions Quote 醫學寫作 香港 醫學作家香港©United States Food and Drug Agency US FDA

Moxetumomab pasudotox-tdfk FDA approved for hairy cell leukaemia

https://medi-paper.com/wp-content/uploads/2018/09/FDA-Logo-2018-MediPR-Medi-Paper-MediPaper-Medical-Communications-Ltd.--e1537925034955.png 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-09-14 14:20:432018-09-14 14:20:43Moxetumomab pasudotox-tdfk FDA approved for hairy cell leukaemia
Adrian TSE HKIOC irAE pneumonitis lung immunotherapy-induced pneumonitis I-O Immuno-Oncology cannonball metastases cancer©MediPaper Medical Communications Ltd

I-O in Special Populations: the Treatment of Immunotherapy-Induced Pneumonitis

https://medi-paper.com/wp-content/uploads/2017/11/Adrian-TSE-HKIOC-irAE-pneumonitis-lung-immunotherapy-induced-pneumonitis-I-O-Immuno-Oncology-cannonball-metastases-cancer.jpg 838 798 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2018-09-14 13:13:492018-09-21 13:56:54I-O in Special Populations: the Treatment of Immunotherapy-Induced Pneumonitis
MediPr medipr.org medi-paper.com MediNews Asia MediNews.asia MediNews.cn MediPaper Medical Communications Ltd Healthcare Writers Medical Writers Medical Writer Agency Hong Kong Medical Writing Services Solutions Quote 醫學寫作 香港 醫學作家香港©United States Food and Drug Agency US FDA

Venetoclax FDA label updated to include Minimal Residual Disease negativity data

https://medi-paper.com/wp-content/uploads/2018/09/FDA-Logo-2018-MediPR-Medi-Paper-MediPaper-Medical-Communications-Ltd.--e1537925034955.png 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-09-12 22:26:092018-09-14 14:25:02Venetoclax FDA label updated to include Minimal Residual Disease negativity data
Quizartinib Receives Orphan Drug Designation for FLT3-Mutated AML in Japan

Quizartinib receives Orphan Drug designation for FLT3-mutated AML in Japan

https://medi-paper.com/wp-content/uploads/2018/09/Quizartinib-Receives-Orphan-Drug-Designation-for-FLT3-Mutated-AML-in-Japan.jpg 1000 1500 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-09-12 22:21:342018-09-12 22:21:34Quizartinib receives Orphan Drug designation for FLT3-mutated AML in Japan
Lung Cancer Capmatinib plus gefitinib promising in MET-dysregulated NSCLC MediPaper Medical Communications Medical Writer Hong Kong 醫學寫作 醫學作家香港© Eraxion / 123RF Stock Photo

Capmatinib plus gefitinib promising in MET-dysregulated NSCLC

https://medi-paper.com/wp-content/uploads/2018/09/Lung-Cancer-Capmatinib-plus-gefitinib-promising-in-MET-dysregulated-NSCLC-MediPaper-Medical-Communications-Medical-Writer-Hong-Kong-醫學寫作-醫學作家香港.png 1000 1500 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-09-11 21:33:342018-09-11 21:48:36Capmatinib plus gefitinib promising in MET-dysregulated NSCLC
CAR-TCR Summit 2018 Preliminary first-in-human data with CAR-Claudin18.2-T in gastric and pancreatic cancer© Royaltystockphoto / 123RF Stock Photo

CAR-TCR Summit 2018: Preliminary first-in-human data with CAR-Claudin18.2-T in gastric and pancreatic cancer

https://medi-paper.com/wp-content/uploads/2018/09/CAR-TCR-Summit-2018-Preliminary-first-in-human-data-with-CAR-Claudin18.2-T-in-gastric-and-pancreatic-cancer.jpg 1054 1505 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-09-09 09:38:282018-09-09 09:38:28CAR-TCR Summit 2018: Preliminary first-in-human data with CAR-Claudin18.2-T in gastric and pancreatic cancer
DRIVER connects cancer patients in China and the United States to the best care© Kentoh / 123RF Stock Photo

DRIVER connects cancer patients in China and the United States to the best care

https://medi-paper.com/wp-content/uploads/2018/09/DRIVER-connects-cancer-patients-in-China-and-the-United-States-to-the-best-care.jpg 994 1500 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-09-07 21:45:362018-09-07 21:45:36DRIVER connects cancer patients in China and the United States to the best care
Blood-based TMB-assay predicts response to atezolizumab in NSCLC patients

Plasma TMB predicts response to atezolizumab in NSCLC patients

https://medi-paper.com/wp-content/uploads/2018/08/Blood-based-TMB-assay-predicts-response-to-atezolizumab-in-NSCLC-patients.jpg 1000 1500 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-08-31 07:42:492018-08-31 14:33:03Plasma TMB predicts response to atezolizumab in NSCLC patients

Edoxaban in Asian patients with atrial fibrillation: effectiveness and safety

https://medi-paper.com/wp-content/uploads/2018/08/cv2.jpg 1000 1500 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-08-29 23:13:062018-08-29 23:13:06Edoxaban in Asian patients with atrial fibrillation: effectiveness and safety

Febuxostat prevents CV events in hyperuricaemia patients

https://medi-paper.com/wp-content/uploads/2018/08/cv4.jpg 1000 1500 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-08-29 11:32:012018-10-04 14:52:10Febuxostat prevents CV events in hyperuricaemia patients
First-in-Class Oncology Vaccine BIL06v Starts Phase 1 Evaluation© luchschen / 123RF Stock Photo

First-in-Class Oncology Vaccine BIL06v Starts Phase 1 Evaluation

https://medi-paper.com/wp-content/uploads/2018/08/First-in-Class-Oncology-Vaccine-BIL06v-Starts-Phase-1-Evaluation.jpg 1000 1500 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-08-22 11:48:172018-08-27 09:35:59First-in-Class Oncology Vaccine BIL06v Starts Phase 1 Evaluation
Nivolumab FDA approved for patients with metastatic small cell lung cancer (SCLC)© FDA

Pembrolizumab and atezolizumab USPIs updated by FDA

https://medi-paper.com/wp-content/uploads/2018/08/fda-e1537925353881.jpg 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-08-21 12:10:412018-08-21 13:18:15Pembrolizumab and atezolizumab USPIs updated by FDA
Nivolumab FDA approved for patients with metastatic small cell lung cancer (SCLC)© FDA

Nivolumab FDA approved for patients with metastatic small cell lung cancer (SCLC)

https://medi-paper.com/wp-content/uploads/2018/08/fda-e1537925353881.jpg 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-08-21 11:24:202018-08-23 10:48:02Nivolumab FDA approved for patients with metastatic small cell lung cancer (SCLC)
Pembrolizumab plus pemetrexed-platinum approved for use in the 1st-line treatment of metastatic non-squamous NSCLC

Pembrolizumab plus pemetrexed-platinum FDA approved for first-line treatment of metastatic non-squamous NSCLC

https://medi-paper.com/wp-content/uploads/2018/08/FDA-approved-lenvatinib-capsules-Lenvima-Eisai-Inc.-for-1st-line-treatment-of-patients-with-unresectable-hepatocellular-carcinoma-HCC.-More-Information-.-August-16-2018-e1537925351885.jpg 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-08-21 10:34:252018-08-21 11:37:56Pembrolizumab plus pemetrexed-platinum FDA approved for first-line treatment of metastatic non-squamous NSCLC
Talazoparib in advanced breast cancer patients with a germline BRCA1:2 mutation

Talazoparib in advanced breast cancer patients with a germline BRCA1/2 mutation

https://medi-paper.com/wp-content/uploads/2018/08/Talazoparib-in-advanced-breast-cancer-patients-with-a-germline-BRCA12-mutation.jpg 687 1030 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-08-19 01:07:502018-08-21 21:55:19Talazoparib in advanced breast cancer patients with a germline BRCA1/2 mutation
CheckMate 032 Nivolumab ipilimumab metastatic esophagogastric cancer

CheckMate 032: Nivolumab +/- ipilimumab for metastatic esophagogastric cancer

https://medi-paper.com/wp-content/uploads/2018/08/CheckMate-032-Nivolumab-ipilimumab-metastatic-esophagogastric-cancer.jpg 667 1000 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-08-18 23:22:562018-08-19 01:08:26CheckMate 032: Nivolumab +/- ipilimumab for metastatic esophagogastric cancer
Pembrolizumab plus pemetrexed-platinum approved for use in the 1st-line treatment of metastatic non-squamous NSCLC

Lenvatinib FDA approved for 1st-line treatment of HCC

https://medi-paper.com/wp-content/uploads/2018/08/FDA-approved-lenvatinib-capsules-Lenvima-Eisai-Inc.-for-1st-line-treatment-of-patients-with-unresectable-hepatocellular-carcinoma-HCC.-More-Information-.-August-16-2018-e1537925351885.jpg 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-08-18 15:50:342018-08-21 22:35:40Lenvatinib FDA approved for 1st-line treatment of HCC
PolyU Researcher Develop Novel Self-fitting Scaffold for Bone-Regeneration©Polytech University Hong Kong

PolyU Researchers Develop Novel Self-fitting Scaffold for Bone-Regeneration

https://medi-paper.com/wp-content/uploads/2018/08/PolyU_bone_regeneration-e1534396913248.jpg 788 1184 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-08-16 13:24:162018-08-16 19:14:03PolyU Researchers Develop Novel Self-fitting Scaffold for Bone-Regeneration
Pan-EGFR TKI pirotinib has commenced into Phase II clinical testing in China©Alex011973 / 123RF Stock Photo

Pan-EGFR TKI pirotinib has commenced into Phase II clinical testing in China

https://medi-paper.com/wp-content/uploads/2018/08/Pan-EGFR-TKI-pirotinib-has-commenced-into-Phase-II-clinical-testing-in-China.jpg 1000 1500 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-08-13 23:09:022018-09-07 21:59:21Pan-EGFR TKI pirotinib has commenced into Phase II clinical testing in China
FDA approved lusutrombopag (Mulpleta, Shionogi Inc.) for thrombocytopenia in adults with chronic liver disease who are scheduled to undergo a medical or dental procedure. More Information.  July 31, 2018.

FDA approved mogamulizumab for adult patients with relapsed or refractory CTCL

https://medi-paper.com/wp-content/uploads/2018/08/FDA-approved-lusutrombopag-Mulpleta-Shionogi-Inc.-for-thrombocytopenia-in-adults-with-chronic-liver-disease-who-are-scheduled-to-undergo-a-medical-or-dental-procedure.-More-Information.-July-31-2018-e1537925382959.jpg 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-08-09 00:58:382018-08-12 12:28:54FDA approved mogamulizumab for adult patients with relapsed or refractory CTCL
FDA approved lusutrombopag (Mulpleta, Shionogi Inc.) for thrombocytopenia in adults with chronic liver disease who are scheduled to undergo a medical or dental procedure. More Information.  July 31, 2018.

Lusutrombopag FDA approved for thrombocytopenia in adult chronic liver disease patients

https://medi-paper.com/wp-content/uploads/2018/08/FDA-approved-lusutrombopag-Mulpleta-Shionogi-Inc.-for-thrombocytopenia-in-adults-with-chronic-liver-disease-who-are-scheduled-to-undergo-a-medical-or-dental-procedure.-More-Information.-July-31-2018-e1537925382959.jpg 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-08-01 09:21:032018-08-12 16:46:52Lusutrombopag FDA approved for thrombocytopenia in adult chronic liver disease patients
Ribociclib FDA label updated to include pre- and perimenopausal women©United States Food and Drug Agency

Iobenguane I-131 FDA approved for rare adrenal neuroendocrine tumours

https://medi-paper.com/wp-content/uploads/2018/06/us-fda-approval-medipaper-medical-communications-agency-medical-writer-agency-apac-asia-pacific-HK-hong-kong-oncology-CV-neurology-immunotherapy-obesity-diabetes-specialty-infectious-e1537925611846.jpg 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-07-31 15:44:032018-07-31 15:45:41Iobenguane I-131 FDA approved for rare adrenal neuroendocrine tumours
T790M osimertinib nsclc brain metastasis CNS metastases Osimertinib in patients With T790M-Positive Advanced Non-Small-Cell Lung Cancer and brain metastases AURA3© srr283/123RF

Osimertinib in patients with T790M-positive advanced non-small cell lung cancer and brain metastases (AURA3)

https://medi-paper.com/wp-content/uploads/2018/08/T790M-osimertinib-nsclc-CNS-brain-metastasis-Osimertinib-in-patients-With-T790M-Positive-Advanced-Non-Small-Cell-Lung-Cancer-and-brain-metastases-AURA3.jpg 1000 1500 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-07-30 23:43:262018-08-20 12:36:41Osimertinib in patients with T790M-positive advanced non-small cell lung cancer and brain metastases (AURA3)

Standard- and low-dose rivaroxaban in Asians with AF: Effectiveness and Safety

https://medi-paper.com/wp-content/uploads/2018/08/cv1.jpg 1000 1500 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-07-30 09:51:512018-08-30 10:05:16Standard- and low-dose rivaroxaban in Asians with AF: Effectiveness and Safety
Anti-PD1 with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma

Anti-PD1 with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma

https://medi-paper.com/wp-content/uploads/2018/08/Anti-PD1-with-Cemiplimab-in-Advanced-Cutaneous-Squamous-Cell-Carcinoma.jpg 1000 1500 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-07-26 23:44:412018-08-22 23:58:36Anti-PD1 with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma
Ribociclib FDA label updated to include pre- and perimenopausal women©United States Food and Drug Agency

Ivosidenib FDA approved for relapsed or refractory acute myeloid leukemia

https://medi-paper.com/wp-content/uploads/2018/06/us-fda-approval-medipaper-medical-communications-agency-medical-writer-agency-apac-asia-pacific-HK-hong-kong-oncology-CV-neurology-immunotherapy-obesity-diabetes-specialty-infectious-e1537925611846.jpg 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-07-23 11:33:402018-07-30 10:43:08Ivosidenib FDA approved for relapsed or refractory acute myeloid leukemia
FDA approved enzalutamide (XTANDI, Astellas Pharma US, Inc.), for patients with castration-resistant prostate cancer (CRPC). More Information.  July 13, 2018

Filgrastim-aafi FDA approved as Filgrastim Biosimilar

https://medi-paper.com/wp-content/uploads/2018/07/FDA-approved-enzalutamide-XTANDI-Astellas-Pharma-US-Inc.-for-patients-with-castration-resistant-prostate-cancer-CRPC.-More-Information-.-July-13-2018-e1537925607982.jpg 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-07-20 10:58:232018-08-11 23:55:01Filgrastim-aafi FDA approved as Filgrastim Biosimilar
Ribociclib FDA label updated to include pre- and perimenopausal women©United States Food and Drug Agency

Ribociclib FDA label updated to include pre- and perimenopausal women

https://medi-paper.com/wp-content/uploads/2018/06/us-fda-approval-medipaper-medical-communications-agency-medical-writer-agency-apac-asia-pacific-HK-hong-kong-oncology-CV-neurology-immunotherapy-obesity-diabetes-specialty-infectious-e1537925611846.jpg 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-07-19 01:01:572018-07-30 10:42:22Ribociclib FDA label updated to include pre- and perimenopausal women
FDA approved enzalutamide (XTANDI, Astellas Pharma US, Inc.), for patients with castration-resistant prostate cancer (CRPC). More Information.  July 13, 2018

Enzalutamide FDA approved for castration-resistant prostate cancer (CRPC)

https://medi-paper.com/wp-content/uploads/2018/07/FDA-approved-enzalutamide-XTANDI-Astellas-Pharma-US-Inc.-for-patients-with-castration-resistant-prostate-cancer-CRPC.-More-Information-.-July-13-2018-e1537925607982.jpg 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-07-17 10:14:112018-07-30 10:42:09Enzalutamide FDA approved for castration-resistant prostate cancer (CRPC)
EBV pembrolizumab gastric cancer - MSI-H pembrolizumab gastric cancer - CPS pembrolizumab gastric cancer - MSI, EBV, CPS predict pembrolizumab outcome in gastric cancer© abhijith3747/123RF

EBV, MSI, and CPS predict pembrolizumab outcome in gastric cancer

https://medi-paper.com/wp-content/uploads/2018/08/EBV-pembrolizumab-gastric-cancer-MSI-H-pembrolizumab-gastric-cancer-CPS-pembrolizumab-gastric-cancer-MSI-EBV-CPS-predict-pembrolizumab-outcome-in-gastric-cancer.jpg 1000 1500 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-07-16 14:03:432018-08-31 08:15:52EBV, MSI, and CPS predict pembrolizumab outcome in gastric cancer
Ribociclib FDA label updated to include pre- and perimenopausal women©United States Food and Drug Agency

Ipilimumab plus nivolumab FDA approved for MSI-H and dMMR pre-treated mCRC

https://medi-paper.com/wp-content/uploads/2018/06/us-fda-approval-medipaper-medical-communications-agency-medical-writer-agency-apac-asia-pacific-HK-hong-kong-oncology-CV-neurology-immunotherapy-obesity-diabetes-specialty-infectious-e1537925611846.jpg 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-07-11 20:52:132018-07-30 10:41:58Ipilimumab plus nivolumab FDA approved for MSI-H and dMMR pre-treated mCRC
Ribociclib FDA label updated to include pre- and perimenopausal women©United States Food and Drug Agency

Combination encorafenib plus binimetinib for unresectable/metastatic BRAF V600E or V600K-positive melanoma FDA approved

https://medi-paper.com/wp-content/uploads/2018/06/us-fda-approval-medipaper-medical-communications-agency-medical-writer-agency-apac-asia-pacific-HK-hong-kong-oncology-CV-neurology-immunotherapy-obesity-diabetes-specialty-infectious-e1537925611846.jpg 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-07-02 22:14:052018-07-30 10:41:23Combination encorafenib plus binimetinib for unresectable/metastatic BRAF V600E or V600K-positive melanoma FDA approved
ASCO 2018 nsclc immunotherapy ASCO18 lung cancer pembrolizumab avelumab nivolumab duravalumab ipilimumab osimertinib dacomitinib lorlatinib crizotinib alectinib keytruda KEYNOTE CheckMate JAVELIN IMpower©eraxion / 123RF Stock Photo

ASCO 2018 NSCLC: The ASCO18 Lung Cancer Track Summarised

https://medi-paper.com/wp-content/uploads/2018/06/ASCO-2018-nsclc-immunotherapy-ASCO18-lung-cancer-pembrolizumab-avelumab-nivolumab-duravalumab-ipilimumab-osimertinib-dacomitinib-lorlatinib-crizotinib-alectinib-keytruda-KEYNOTE-CheckMate-JAVELIN-IMpower.jpg 1000 1500 Anne John Michael https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Anne John Michael2018-06-25 18:22:252018-08-21 11:43:54ASCO 2018 NSCLC: The ASCO18 Lung Cancer Track Summarised
FDA  has limited the use of Tecentriq and Keytruda for patients with locally advanced or metastatic urothelial cancer who are not eligible for cisplatin-containing therapy.  More Information.  June 19, 2018

FDA limits use of atezolizumab and pembrolizumab in urothelial carcinoma

https://medi-paper.com/wp-content/uploads/2018/07/FDA-has-limited-the-use-of-Tecentriq-and-Keytruda-for-patients-with-locally-advanced-or-metastatic-urothelial-cancer-who-are-not-eligible-for-cisplatin-containing-therapy.-More-Information-.-June-19-2018-e1537925445648.jpg 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-06-19 14:01:322018-07-30 10:40:51FDA limits use of atezolizumab and pembrolizumab in urothelial carcinoma
ASCO 2018 breast cancer TNBC MBC ABC ASCO18 PHEREXA D-CARE ABCSG-18 ASTRRA TEXT SOFT MONARCH-2 MONALEESA-3 SANDPIPER BOLERO-6 TOPACIO KEYNOTE-162 TONIC TOPACIO GeparNeuvo©eraxion / 123RF Stock Photo

ASCO 2018 Breast Cancer: The ASCO18 breast cancer track summarised

https://medi-paper.com/wp-content/uploads/2018/06/ASCO-2018-breast-cancer-TNBC-MBC-ABC-ASCO18-PHEREXA-D-CARE-ABCSG-18-ASTRRA-TEXT-SOFT-MONARCH-2-MONALEESA-3-SANDPIPER-BOLERO-6-TOPACIO-KEYNOTE-162-TONIC-TOPACIO-GeparNeuvo.jpg 1000 1500 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2018-06-19 09:02:512018-06-19 23:57:08ASCO 2018 Breast Cancer: The ASCO18 breast cancer track summarised
Ribociclib FDA label updated to include pre- and perimenopausal women©United States Food and Drug Agency

Bevacizumab in combination with carboplatin and paclitaxel FDA approved for several types of gynaecological cancers

https://medi-paper.com/wp-content/uploads/2018/06/us-fda-approval-medipaper-medical-communications-agency-medical-writer-agency-apac-asia-pacific-HK-hong-kong-oncology-CV-neurology-immunotherapy-obesity-diabetes-specialty-infectious-e1537925611846.jpg 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-06-14 22:56:042018-07-30 10:40:22Bevacizumab in combination with carboplatin and paclitaxel FDA approved for several types of gynaecological cancers
Ribociclib FDA label updated to include pre- and perimenopausal women©United States Food and Drug Agency

FDA approved pembrolizumab for 3rd-line PMBCL in adult and pediatric patients

https://medi-paper.com/wp-content/uploads/2018/06/us-fda-approval-medipaper-medical-communications-agency-medical-writer-agency-apac-asia-pacific-HK-hong-kong-oncology-CV-neurology-immunotherapy-obesity-diabetes-specialty-infectious-e1537925611846.jpg 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-06-14 22:42:142018-07-30 10:40:10FDA approved pembrolizumab for 3rd-line PMBCL in adult and pediatric patients
Ribociclib FDA label updated to include pre- and perimenopausal women©United States Food and Drug Agency

FDA approved pembrolizumab for chemotherapy-refractory r/m cervical cancer with PD-L1 CPS ≥1 

https://medi-paper.com/wp-content/uploads/2018/06/us-fda-approval-medipaper-medical-communications-agency-medical-writer-agency-apac-asia-pacific-HK-hong-kong-oncology-CV-neurology-immunotherapy-obesity-diabetes-specialty-infectious-e1537925611846.jpg 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-06-13 21:59:012018-07-30 10:39:54FDA approved pembrolizumab for chemotherapy-refractory r/m cervical cancer with PD-L1 CPS ≥1 
ASCO18 ASCO 2018 HCC hepatocellular carcinoma liver cancer pembrolizumab KEYTRUDA atezolizumab TECENTRIQ PD-1 PD-L1 immunecheckpoint immunotherapy ramucirumab cabozantinib KEYNOTE-224 SCRUM-Japan GI-SCREEN CELESTIAL REACH-2© krishnacreations / 123RF Stock Photo

ASCO 2018 HCC: The ASCO18 hepatocellular cancer track summarised

https://medi-paper.com/wp-content/uploads/2018/06/ASCO18-ASCO-2018-HCC-hepatocellular-carcinoma-liver-cancer-pembrolizumab-KEYTRUDA-atezolizumab-TECENTRIQ-PD-1-PD-L1-immunecheckpoint-immunotherapy-ramucirumab-cabozantinib-KEYNOTE-224-SCRUM-Japan-GI-SCREEN-CELESTIAL-REACH-2.jpg 1000 1500 Anne John Michael https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Anne John Michael2018-06-10 11:59:542018-08-23 10:33:26ASCO 2018 HCC: The ASCO18 hepatocellular cancer track summarised
Ribociclib FDA label updated to include pre- and perimenopausal women©United States Food and Drug Agency

FDA approves venetoclax in 2nd-line for patients with CLL or SLL

https://medi-paper.com/wp-content/uploads/2018/06/us-fda-approval-medipaper-medical-communications-agency-medical-writer-agency-apac-asia-pacific-HK-hong-kong-oncology-CV-neurology-immunotherapy-obesity-diabetes-specialty-infectious-e1537925611846.jpg 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-06-09 11:25:082018-09-25 17:51:30FDA approves venetoclax in 2nd-line for patients with CLL or SLL
Ribociclib FDA label updated to include pre- and perimenopausal women©United States Food and Drug Agency

FDA approved biosimilar pegfilgrastim to decrease the chance of febrile neutropenia in patients with non-myeloid cancers on myelosuppressive chemotherapy

https://medi-paper.com/wp-content/uploads/2018/06/us-fda-approval-medipaper-medical-communications-agency-medical-writer-agency-apac-asia-pacific-HK-hong-kong-oncology-CV-neurology-immunotherapy-obesity-diabetes-specialty-infectious-e1537925611846.jpg 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-06-06 16:07:462018-08-11 23:55:46FDA approved biosimilar pegfilgrastim to decrease the chance of febrile neutropenia in patients with non-myeloid cancers on myelosuppressive chemotherapy
IMPower150 Reck Socinski ELCC AACR 2018 firstline atezolizumab bevacizumab chemotherapy non-squamous nsclcbravajulia / 123RF Stock Photo

AACR 2018: first-line atezolizumab, bevacizumab plus chemotherapy active in non-squamous NSCLC

https://medi-paper.com/wp-content/uploads/2018/05/IMPower150-Reck-Socinski-ELCC-AACR-2018-firstline-atezolizumab-bevacizumab-chemotherapy-non-squamous-nsclc.jpg 1000 1500 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2018-05-10 16:19:462018-05-24 09:31:31AACR 2018: first-line atezolizumab, bevacizumab plus chemotherapy active in non-squamous NSCLC
US FDA approved CAR-t cell BiTE DAR-T cell CD19 Immunotherapies blinatumomab axicabtagene ciloleucel tisagenlecleucel

US FDA approved CAR-T cell and BiTE immunotherapy – Updated 2-May-2018

https://medi-paper.com/wp-content/uploads/2018/04/US-FDA-approved-CAR-t-cell-BiTE-DAR-T-cell-CD19-Immunotherapies-blinatumomab-axicabtagene-ciloleucel-tisagenlecleucel.jpg 1000 1500 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2018-05-02 10:00:352018-05-24 09:36:21US FDA approved CAR-T cell and BiTE immunotherapy – Updated 2-May-2018
Ribociclib FDA label updated to include pre- and perimenopausal women©United States Food and Drug Agency

Adjuvant dabrafenib plus trametinib FDA approved for BRAF V600E or V600K melanoma

https://medi-paper.com/wp-content/uploads/2018/06/us-fda-approval-medipaper-medical-communications-agency-medical-writer-agency-apac-asia-pacific-HK-hong-kong-oncology-CV-neurology-immunotherapy-obesity-diabetes-specialty-infectious-e1537925611846.jpg 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-04-30 13:35:562018-07-30 11:42:21Adjuvant dabrafenib plus trametinib FDA approved for BRAF V600E or V600K melanoma
AACR 2018 First-line Nivolumab-Ipilimumab in TMB-high NSCLC front-line immunotherapy for non-small cell lung cancer tumour-mutation burden CheckMate 227 NCT02477826Hywards / 123RF Stock Photo

Nivolumab-Ipilimumab Combination: A New Option for TMB-High NSCLC (CheckMate 227)

https://medi-paper.com/wp-content/uploads/2018/04/First-line-Nivolumab-Ipilimumab-in-TMB-high-NSCLC-front-line-immunotherapy-for-non-small-cell-lung-cancer-CheckMate-227-NCT02477826.jpg 1000 1500 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2018-04-21 10:30:432018-05-24 09:37:03Nivolumab-Ipilimumab Combination: A New Option for TMB-High NSCLC (CheckMate 227)
Ribociclib FDA label updated to include pre- and perimenopausal women©United States Food and Drug Agency

FDA approved osimertinib for the 1st-line treatment of patients with EGFR exon 19 deletions or exon 21 L858R mutations positive metastatic non-small cell lung cancer (NSCLC)

https://medi-paper.com/wp-content/uploads/2018/06/us-fda-approval-medipaper-medical-communications-agency-medical-writer-agency-apac-asia-pacific-HK-hong-kong-oncology-CV-neurology-immunotherapy-obesity-diabetes-specialty-infectious-e1537925611846.jpg 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-04-19 13:36:062018-07-30 11:15:04FDA approved osimertinib for the 1st-line treatment of patients with EGFR exon 19 deletions or exon 21 L858R mutations positive metastatic non-small cell lung cancer (NSCLC)
NCT02578680 Keynote189 AACR 2018 pembrolizumab chemotherapy nsclc NEJM Leena Gandhikrishnacreations / 123RF Stock Photo

Frontline Combination of Pembrolizumab and Chemotherapy: A New Standard of Care for Non-squamous NSCLC

https://medi-paper.com/wp-content/uploads/2018/04/NCT02578680-Keynote189-pembrolizumab-chemotherapy-nsclc-NEJM-Leena-Gandhi.jpg 938 1500 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2018-04-19 01:27:262018-05-24 09:37:16Frontline Combination of Pembrolizumab and Chemotherapy: A New Standard of Care for Non-squamous NSCLC
Ribociclib FDA label updated to include pre- and perimenopausal women©United States Food and Drug Agency

Frontline nivolumab plus ipilimumab approved for intermediate or poor risk advanced RCC

https://medi-paper.com/wp-content/uploads/2018/06/us-fda-approval-medipaper-medical-communications-agency-medical-writer-agency-apac-asia-pacific-HK-hong-kong-oncology-CV-neurology-immunotherapy-obesity-diabetes-specialty-infectious-e1537925611846.jpg 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-04-16 13:59:012018-07-30 11:50:31Frontline nivolumab plus ipilimumab approved for intermediate or poor risk advanced RCC
Keynote-042 Keynote-024 pembrolizumab nsclc keytruda nsclc non-squamous squamous PD-L1 expression 1% 20% 50% Tony Mok MD NCT02220894 Pembrolizumab effective in frontline NSCLC with low PD-L1 expression

Pembrolizumab effective in frontline NSCLC with low PD-L1 expression

https://medi-paper.com/wp-content/uploads/2018/04/Keynote-042-Keynote-024-pembrolizumab-nsclc-keytruda-nsclc-non-squamous-squamous-PD-L1-expression-1-20-50-Tony-Mok-MD-NCT02220894-Pembrolizumab-effective-in-frontline-NSCLC-with-low-PD-L1-expression.jpg 1000 1500 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2018-04-10 20:15:112018-05-24 09:37:32Pembrolizumab effective in frontline NSCLC with low PD-L1 expression
Ribociclib FDA label updated to include pre- and perimenopausal women©United States Food and Drug Agency

Everolimus suspension approved in TSC-associated partial-onset seizures

https://medi-paper.com/wp-content/uploads/2018/06/us-fda-approval-medipaper-medical-communications-agency-medical-writer-agency-apac-asia-pacific-HK-hong-kong-oncology-CV-neurology-immunotherapy-obesity-diabetes-specialty-infectious-e1537925611846.jpg 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-04-10 14:07:302018-07-30 14:22:09Everolimus suspension approved in TSC-associated partial-onset seizures
Herbert Loong on irAEs Immunotherapy (I-O) and New Onset Diabetes or immune-mediated diabetes

I-O in Special Populations: Diabetes and Concomitant Steroids

https://medi-paper.com/wp-content/uploads/2018/02/Herbert-Loong-on-irAEs-Immunotherapy-I-O-and-New-Onset-Diabetes-or-immune-mediated-diabetes.jpg 1000 1500 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2018-04-06 09:00:412018-08-11 23:56:01I-O in Special Populations: Diabetes and Concomitant Steroids
Crizotinib beneficial for East-Asian NSCLC-patients with ROS1 alterations crizotinib asian crizotinib ros1 crizotinib asian nsclc patients crizotinib asian non-small cell lung cancer patients

Crizotinib beneficial for East-Asian NSCLC patients with ROS1 alterations

https://medi-paper.com/wp-content/uploads/2018/04/Crizotinib-beneficial-for-East-Asian-NSCLC-patients-with-ROS1-alterations-crizotinib-asian-crizotinib-ros1-crizotinib-asian-nsclc-patients-crizotinib-asian-non-small-cell-lung-cancer-patients-e1522913753323.jpg 1000 1500 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2018-04-04 16:00:112018-04-19 13:57:57Crizotinib beneficial for East-Asian NSCLC patients with ROS1 alterations

Death due to cancer on the decline for most tumours in Europe

https://medi-paper.com/wp-content/uploads/2018/03/1522336566_Oncology-Breast-CNS-Chemotherapy-Endocrine-GI-GU-Geriatric-Gynecologic-GYN-OB-Head-and-Neck-Haematology-Immunotherapy-Lung-Melanoma-Skin-NET-Paediatric-Pathology-Sarcoma-Surgery-Targeted-Therapy-Translational-03.jpg 277 450 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2018-03-31 11:03:502018-08-10 11:57:59Death due to cancer on the decline for most tumours in Europe
immunotherapy I-O immunooncology nivolumab npc opdivo nasopharyngeal carcinoma brigette ma CUHK phase II nci-9742 study JCO journal of clinical oncology

Nivolumab for NPC: immunotherapy active in nasopharyngeal carcinoma (NCI-9742)

https://medi-paper.com/wp-content/uploads/2018/03/nivolumab-npc-opdivo-nasopharyngeal-carcinoma-brigette-ma-CUHK-phase-II-nci-9742-study-JCO-journal-of-clinical-oncology.jpg 1000 1500 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2018-03-31 09:20:312018-05-24 09:38:41Nivolumab for NPC: immunotherapy active in nasopharyngeal carcinoma (NCI-9742)
©aquir / 123RF Stock Photo

FDA granted accelerated approval to blinatumomab for the treatment of adult and paediatric patients with B-cell precursor ALL in first or second complete remission with MRD ≥0.1%

https://medi-paper.com/wp-content/uploads/2018/05/1526019694_US-FDA-Oncology-Haematology-Drug-Approvals-e1537929700820.jpg 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-03-29 14:21:342018-09-25 17:51:10FDA granted accelerated approval to blinatumomab for the treatment of adult and paediatric patients with B-cell precursor ALL in first or second complete remission with MRD ≥0.1%
manuela schmidinger sutent sunitinib ae management manuela schmidinger manuela schmidinger sutent sunitinib side-effect management sutent sunitinib toxicity management Sutent Sunitinib AE management toxicity management side-effect management sorafenib pazopanib axitinib regorafenib vandetanib cabozantinib lenvatinib bevacizumab VEGFR VEGF renal cell carcinoma RCC kidney cancer renal cell cancer schmidinger

Achieving Long-Term Survival in the First-Line Treatment of Metastatic Renal Cell Carcinoma; A Balancing Act of Efficacy and Side-Effects

https://medi-paper.com/wp-content/uploads/2017/11/image.png 852 1471 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2017-11-29 22:12:232018-04-19 10:46:51Achieving Long-Term Survival in the First-Line Treatment of Metastatic Renal Cell Carcinoma; A Balancing Act of Efficacy and Side-Effects
ASPEN CSA 2017 Prof Xue Zhanggang on TIVA Enhanced Recovery by Optimized Anesthetics

TIVA: enhanced recovery by optimized anesthetics

https://medi-paper.com/wp-content/uploads/2017/11/ASPEN-CSA-2017-Prof-Xue-Zhanggang-on-TIVA-Enhanced-Recovery-by-Optimized-Anesthetics.jpeg 1000 1500 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2017-11-23 16:06:422018-09-26 11:37:43TIVA: enhanced recovery by optimized anesthetics
2016 pancreatic cancer awareness month IMM-101 plus Gemcitabine medipaper medical communications medical writer hire healthcare writers hong kong

Do you know your lifetime risk on Pancreatic Cancer?

https://medi-paper.com/wp-content/uploads/2016/11/2016-Pancreatic-Cancer-medipaper-medical-communications-medical-writer-hire-healthcare-writers-hong-kong.jpg 844 1500 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2017-11-20 12:29:422018-02-09 14:08:00Do you know your lifetime risk on Pancreatic Cancer?
Aspen CSA2017 the status of ERAS in China CSA2017 on the use of ERAS and TIVA in China

CSA2017: Prof Huang Yuguang on the use of ERAS and TIVA in China

https://medi-paper.com/wp-content/uploads/2017/11/Aspen-CSA2017-the-status-of-ERAS-in-China-CSA2017-on-the-use-of-ERAS-and-TIVA-in-China-1030x687.jpg 687 1030 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2017-11-07 22:23:132018-09-26 11:38:14CSA2017: Prof Huang Yuguang on the use of ERAS and TIVA in China
Aspen CSA2017 the status of ERAS in China CSA2017 on the use of ERAS and TIVA in China

CSA2017: Prof Xiong Lize on the status of ERAS in China

https://medi-paper.com/wp-content/uploads/2017/11/Aspen-CSA2017-the-status-of-ERAS-in-China-CSA2017-on-the-use-of-ERAS-and-TIVA-in-China-1030x687.png 687 1030 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2017-11-07 20:54:572018-09-26 11:38:41CSA2017: Prof Xiong Lize on the status of ERAS in China
HKBCF luminal breast cancer can cdk46 inhibition by palbociclib improve on chemotherapy medipaper medical writer hong kong

Luminal Breast Cancer: can CDK4/6 Inhibition by Palbociclib Improve on Chemotherapy?

https://medi-paper.com/wp-content/uploads/2017/10/HKBCF-luminal-breast-cancer-can-cdk46-inhibition-by-palbociclib-improve-on-chemotherapy-medipaper-medical-writer-hong-kong.jpg 1000 1500 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2017-10-25 22:58:382018-02-09 14:08:00Luminal Breast Cancer: can CDK4/6 Inhibition by Palbociclib Improve on Chemotherapy?
us-fda-approval-medipaper-medical-communications-agency-medical-writer-agency-apac-asia-pacific-HK-hong-kong-oncology-CV-neurology-immunotherapy-obesity-diabetes-specialty-infectious.jpg

Pembrolizumab approved for advanced gastric cancer

https://medi-paper.com/wp-content/uploads/2018/07/us-fda-approval-medipaper-medical-communications-agency-medical-writer-agency-apac-asia-pacific-HK-hong-kong-oncology-CV-neurology-immunotherapy-obesity-diabetes-specialty-infectious-e1537925322207.jpg 1000 1495 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2017-09-22 23:33:522018-07-26 15:04:47Pembrolizumab approved for advanced gastric cancer
us-fda-approval-medipaper-medical-communications-agency-medical-writer-agency-apac-asia-pacific-HK-hong-kong-oncology-CV-neurology-immunotherapy-obesity-diabetes-specialty-infectious.jpg

Nivolumab approved for sorafenib-refractory HCC

https://medi-paper.com/wp-content/uploads/2018/07/us-fda-approval-medipaper-medical-communications-agency-medical-writer-agency-apac-asia-pacific-HK-hong-kong-oncology-CV-neurology-immunotherapy-obesity-diabetes-specialty-infectious-e1537925322207.jpg 1000 1495 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2017-09-22 23:21:412018-07-26 11:42:35Nivolumab approved for sorafenib-refractory HCC
Nivolumab Renal Cell Cancer Symposium Highlight

Nivolumab for Renal Carcinoma: Getting the Most Out of PD-1 Immunotherapy

https://medi-paper.com/wp-content/uploads/2017/09/Nivolumab-Renal-Cell-Cancer-Symposium-Highlight.jpg 1000 1500 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2017-09-19 23:04:512018-08-11 23:56:17Nivolumab for Renal Carcinoma: Getting the Most Out of PD-1 Immunotherapy
CSA2017 中华医学会第25 次全国麻醉学术年会 2017 郑州 25th Annual Meeting of the Chinese Society of AnaesthesiologyCSA 2017

25th Annual Meeting of the Chinese Society of Anaesthesiology

https://medi-paper.com/wp-content/uploads/2017/09/CSA2017-0-中华医学会第25-次全国麻醉学术年会-2017-郑州-25th-Annual-Meeting-of-the-Chinese-Society-of-Anaesthesiology.jpg 684 845 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2017-09-06 18:03:272018-05-11 10:15:3625th Annual Meeting of the Chinese Society of Anaesthesiology
adjuvant hormonal therapy

Should all Women with Endocrine-Sensitive and Operable Breast Cancer Receive Adjuvant Hormonal Therapy?

https://medi-paper.com/wp-content/uploads/2017/08/adjuvant-hormonal-therapy.jpg 1000 1500 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2017-07-05 22:46:312018-02-09 14:08:00Should all Women with Endocrine-Sensitive and Operable Breast Cancer Receive Adjuvant Hormonal Therapy?
2017 CICS immunooncology annual meeting oncology medical writer medipaper medical communications

Interested in Attending an Immunooncology Conference?

https://medi-paper.com/wp-content/uploads/2017/02/2017-CICS-immunooncology-annual-meeting-oncology-medical-writer-medipaper-medical-communications.png 1000 1500 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2017-06-21 16:05:482018-02-09 14:08:00Interested in Attending an Immunooncology Conference?
AMNOG Germany Pharmaceuticals Pricing Legislation MediPaper Medical Writer Hong Kong

AMNOG: Germany Pharmaceuticals Pricing Legislation Overview

https://medi-paper.com/wp-content/uploads/2016/12/AMNOG-Germany-Pharmaceuticals-Pricing-Legislation-MediPaper-Medical-Writer-Hong-Kong.jpg 1000 1500 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2016-12-15 15:12:092018-02-09 13:51:11AMNOG: Germany Pharmaceuticals Pricing Legislation Overview
esmo 2016 breast cancer ribociclib palbociclib abemaciclib data medipaper medicall writer

ESMO16 Breast Cancer: Palbociclib, Ribociclib and Abemaciclib Data

https://medi-paper.com/wp-content/uploads/2016/10/ESMO-2016-Breast-Cancer-Palbociclib-Ribociclib-Abemaciclib-data-MediPaper-Medical-Writer-e1478671413852.jpg 1000 1500 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2016-11-09 16:00:442018-05-11 17:14:06ESMO16 Breast Cancer: Palbociclib, Ribociclib and Abemaciclib Data
PD-L1 Biomarker for Response DAKO 22C3 - MediPaper Medical Communications

PD-L1 Biomarker: a Comparison of ASCO2016 PD-1 and PD-L1 Data

https://medi-paper.com/wp-content/uploads/2016/08/PD-L1-Biomarker-for-Response-DAKO-22C3-MediPaper-Medical-Communications.jpg 1000 1500 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2016-10-26 14:00:352018-05-11 17:21:18PD-L1 Biomarker: a Comparison of ASCO2016 PD-1 and PD-L1 Data
Biomarkers Ipilimumab Treatment MediPaper Medical Communications

Novel Biomarker for Ipilimumab Treatment may aid Future Patient Selection in Several Malignancies

https://medi-paper.com/wp-content/uploads/2016/10/Biomarkers-Ipilimumab-Treatment-MediPaper-Medical-Communications.jpg 1000 1500 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2016-10-24 10:12:072018-05-11 17:18:58Novel Biomarker for Ipilimumab Treatment may aid Future Patient Selection in Several Malignancies
ESMO 2016 ipilimumab data medipaper medical communications

ESMO16 Ipilimumab data – Download the PPT

https://medi-paper.com/wp-content/uploads/2016/09/ESMO-2016-ipilimumab-data-medipaper.jpg 667 1000 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2016-10-11 11:10:102018-05-11 17:28:19ESMO16 Ipilimumab data – Download the PPT
ESMO 2016 pembrolizumab data medipaper medical communications

ESMO16 Pembrolizumab data – Download the PPT

https://medi-paper.com/wp-content/uploads/2016/09/ESMO-2016-pembrolizumab-data-medipaper.jpg 667 1000 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2016-10-10 21:08:122018-05-11 17:28:28ESMO16 Pembrolizumab data – Download the PPT
ESMO 2016 durvalumab avelumab tremelimumab data medipaper medical communications

ESMO16 Durvalumab, Avelumab, Tremelimumab Data – Download the PPT

https://medi-paper.com/wp-content/uploads/2016/10/ESMO-2016-durvalumab-avelumab-tremelimumab-data-medipaper.jpg 667 1000 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2016-10-10 10:30:512018-05-11 17:28:38ESMO16 Durvalumab, Avelumab, Tremelimumab Data – Download the PPT
ESMO 2016 atezolizumab data medipaper medical communications

ESMO16 Atezolizumab data – Download the PPT

https://medi-paper.com/wp-content/uploads/2016/09/ESMO-2016-atezolizumab-data-medipaper.jpg 665 1000 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2016-10-09 17:50:232018-05-11 17:28:52ESMO16 Atezolizumab data – Download the PPT
ESMO 2016 nivolumab data medipaper medical communications

ESMO16 Nivolumab data – Download the PPT

https://medi-paper.com/wp-content/uploads/2016/09/ESMO-2016-nivolumab-data-medipaper.jpg 667 1000 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2016-10-09 16:30:582018-05-11 17:29:00ESMO16 Nivolumab data – Download the PPT
cancer awareness improves outcome medipaper medical communications

Cancer symptom awareness linked to survival

https://medi-paper.com/wp-content/uploads/2016/09/cancer-awareness-improves-outcome-medipaper-medical-communications.jpg 1000 1500 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2016-09-30 21:33:432018-02-09 13:51:10Cancer symptom awareness linked to survival
2016 ASCO ovarian cancer guidelines neo-adjuvant chemotherapy medipaper medical communications

ASCO Guideline NeoAdjuvant Chemotherapy for Ovarian Cancer Updated

https://medi-paper.com/wp-content/uploads/2016/09/2016-asco-ovarian-cancer-guidelines-neo-adjuvant-chemotherapy-medipaper-medical-communications-e1478394814429.png 1000 1500 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2016-09-27 21:53:422018-02-09 14:07:58ASCO Guideline NeoAdjuvant Chemotherapy for Ovarian Cancer Updated
IMM-101 plus gemcitabine-medipaper medical communications BW

IMM101 plus Gemcitabine Hopeful in Metastatic Pancreatic Cancer

https://medi-paper.com/wp-content/uploads/2016/09/IMM-101-plus-gemcitabine-medipaper-medical-communications_medical_writer_hong_kong.jpg 844 1500 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2016-09-25 00:19:582018-02-09 13:51:09IMM101 plus Gemcitabine Hopeful in Metastatic Pancreatic Cancer
palbociclib-first-in-class

Palbociclib (Ibrance®): First in Class CDK4/6 Inhibitor

https://medi-paper.com/wp-content/uploads/2016/04/palbociclib-first-in-class.jpg 662 1095 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2016-09-17 00:46:162018-05-11 17:13:52Palbociclib (Ibrance®): First in Class CDK4/6 Inhibitor
Ki67 breast cancer medical writer epotomics

Ki67 in Breast Cancer: an overview

https://medi-paper.com/wp-content/uploads/2016/04/Ki67-breast-cancer-medical-writer-epotomics-com.png 998 1500 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2016-09-06 00:07:072018-05-11 17:15:08Ki67 in Breast Cancer: an overview
ASCO 2016 ribociclib & abemaciclib Data - MediPaper Medical Communications

ASCO16 Ribociclib & Abemaciclib Data

https://medi-paper.com/wp-content/uploads/2016/06/ribociclib-abemaciclib-ASCO2016-Data-MediPaper-Medical-Communications.jpg 1033 1500 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2016-06-05 23:30:482018-05-11 17:17:01ASCO16 Ribociclib & Abemaciclib Data
ASCO 2016 Palbociclib Data MediPaper Medical Communications

ASCO16 palbociclib (Ibrance©) Data

https://medi-paper.com/wp-content/uploads/2016/06/ASCO-2016-Palbociclib-Data-MediPaper-Medical-Communications.jpg 1000 1500 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2016-06-04 22:51:302018-05-11 17:16:17ASCO16 palbociclib (Ibrance©) Data
ASCO 2016 Avelumab Durvalumab and Tremelimumab Data - MediPaper Medical Communications

ASCO16 Avelumab, Durvalumab, and Tremelimumab

https://medi-paper.com/wp-content/uploads/2016/06/ASCO-2016-Azelumab-Durvalumab-and-Tremelimumab-Data.jpg 938 1500 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2016-06-03 11:57:432018-05-11 17:25:17ASCO16 Avelumab, Durvalumab, and Tremelimumab
asco 2016 atezolizumab data

ASCO16 Atezolizumab (Tecentriq©) Data

https://medi-paper.com/wp-content/uploads/2016/06/asco-2016-atezolizumab-data.jpg 1024 1536 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2016-06-02 15:15:132018-05-11 17:25:04ASCO16 Atezolizumab (Tecentriq©) Data
ASCO2016 ipilimumab data - MediPaper Medical Communications

ASCO16 Ipilimumab (Yervoy©) Data

https://medi-paper.com/wp-content/uploads/2016/05/ASCO2016-ipilimumab-data-MediPaper-Medical-Communications.jpg 938 1500 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2016-05-31 13:05:442018-05-11 17:22:00ASCO16 Ipilimumab (Yervoy©) Data
asco 2016 nivolumab medipaper medical communications

ASCO16 Nivolumab (Opdivo©) Data

https://medi-paper.com/wp-content/uploads/2016/05/asco-2016-nivolumab.jpg 1000 1500 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2016-05-29 00:44:422018-05-11 17:25:59ASCO16 Nivolumab (Opdivo©) Data
asco 2016 pembrolizumab medipaper medical communications

ASCO16 Pembrolizumab (Keytruda©) Data

https://medi-paper.com/wp-content/uploads/2016/05/asco-2016-pembrolizumab.jpg 851 1500 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2016-05-29 00:23:322018-05-11 17:22:45ASCO16 Pembrolizumab (Keytruda©) Data
asco 2016 immune checkpoint inhibitors

ACC2016: 8½ Important Cardiology Lessons Learned

https://medi-paper.com/wp-content/uploads/2016/04/acc2016-chicago-take-away-messages.jpg 1024 1536 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2016-04-04 22:11:202017-11-25 14:09:33ACC2016: 8½ Important Cardiology Lessons Learned
PreviousNext
5 replies

Trackbacks & Pingbacks

  1. Approved Immune-Checkpoint Inhibitors and Immunotherapies says:
    8th October 2018 at 10:26 PM

    […] non-small cell lung cancer (NSCLC) with PD-L1 TPS (tumour proportion score) ≥1% […]

    Log in to Reply
  2. Plasma-TMB predicts response to atezolizumab in NSCLC patients says:
    31st August 2018 at 12:29 PM

    […] programmed death 1 (PD-1)–axis have demonstrated significant overall survival (OS) benefit in the 2nd-line treatment for advanced NSCLC. Tumour- and immune-cell PD-1 ligand (PD-L1) expression has shown to partially predict the clinical […]

    Log in to Reply
  3. ASCO 2018 NSCLC: The ASCO18 Lung Cancer Track Summarised says:
    25th June 2018 at 6:22 PM

    […] Non-small cell lung cancer (NSCLC) is a key feature of the American Society of Clinical Oncology (ASCO) 2018 annual meeting. This year, encouraging results with combinations therapies were presented, including CheckMate 227 with nivolumab (NIVO), IMpower131 and IMpower150 studies with atezolizumab (ATEZO), and KEYNOTE-042 and KEYNOTE-407 studies with pembrolizumab (PEMBRO). Important Asian data on treatments for epidermal growth-factor recptor (EGFR) mutation-positive (mu+) NSCLC (ARCHER 1050, NEJ009, NEJ026, and JO25567) were also featured. Welcome to the summary of the ASCO 2018 NSCLC track. […]

    Log in to Reply
  4. Approved Immune-Checkpoint Inhibitors and Immunotherapies per 23-APR-2018 says:
    24th May 2018 at 9:37 AM

    […] non-small cell lung cancer (NSCLC) with PD-L1 TPS (tumour proportion score) ≥1% […]

    Log in to Reply
  5. AACR 2018: First-line atezolizumab, bevacizumab plus chemotherapy active in non-squamous NSCLC says:
    24th May 2018 at 9:32 AM

    […] with advanced non-squamous non-small cell lung cancer (NSCLC) treated with first-line atezolizumab (Tecentriq®) plus bevacizumab (Avastin®), carboplatin, and […]

    Log in to Reply

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply Cancel reply

You must be logged in to post a comment.

© Copyright 2018 MediPaper Medical Communications Ltd. – Making sense of immunotherapy for non-small cell lung cancer (NSCLC)

Therapeutic Areas

Login

or
Login with Google
Login with Facebook
Login with Twitter
Login with LinkedIn
  • Register
  • Lost your password?

Or, sign up for our newsletter


 MediPR | MediPaper Healthcare Writers | Digital Medical Marketing | Medical Writing Solutions 醫學寫作 | Medical Writing Quote | Medical Writing Portfolio | Medical Writer Hong Kong 醫學作家香港 | Hire Healthcare Writers Hong Kong | Contact our Medical Writer Agency | MediPaper Health News | Medical Writer Jobs | PMHub
© 2016-2021 MediPaper Medical Communications Ltd. | Website by [’mediPr] | 醫學作家香港 | Privacy Policy | Cookie Policy
  • Facebook
  • LinkedIn
  • Twitter
  • Instagram
  • Pinterest
  • Youtube
  • Mail
  • Rss
FDA approved nilotinib for paediatric patients with newly diagnosed Ph+ CML-CP... Trials Consider Role of Immunotherapy in Breast Cancer Trials Consider Role of Immunotherapy in Breast Cancer
Scroll to top

This site uses cookies to improve your experience. By continuing to browse the site, you are agreeing to our use of cookies.

OKPrivacy Settings

Cookies and Privacy on medi-paper.com



Cookie Policy

How MediPaper uses cookies is explained in our Cookie Policy

Privacy Policy

Read MediPaper's Privacy Policy

Google Analytics cookies

These cookies collect information that is used either in aggregate form to help us understand how our website is being used or how effective our marketing campaigns are, or to help us customize our website and application for you in order to enhance your experience.

If you do not want that we track your visist to our site you can disable tracking in your browser here:

Other external services

We also use different external services like Google Webfonts, Google Maps and external Video providers. Since these providers may collect personal data like your IP address we allow you to block them here. Please be aware that this might heavily reduce the functionality and appearance of our site. Changes will take effect once you reload the page.

Google Webfont Settings:

Google Map Settings:

Vimeo and Youtube video embeds:

Accept settingsHide notification only
Copy link
CopyCopied